JOHNSON & JOHNSON 853260 - wohl das am konstantesten wachsende Unternehmen der Welt - 500 Beiträge pro Seite

eröffnet am 22.11.07 16:46:06 von
neuester Beitrag 18.01.21 16:16:49 von

ISIN: US4781601046 | WKN: 853260 | Symbol: JNJ
160,30
$
15.01.21
NYSE
-0,22 %
-0,35 USD

Beitrag schreiben

Begriffe und/oder Benutzer

 

Avatar
22.11.07 16:46:06
Hallo,

wollte mal zu JOHNSON & JOHNSON (WKN: 853260, Kürzel: JNJ) einen Thread aufmachen, da es zu diesem Unternehmen keinen gibt, wohl deshalb, weil die Kursentwicklung langweilig ist.
Jedoch gibt es für den Langfristinvestor kaum ein Unternehmen, bei dem er sich beteiligen kann, das so eine konstante Entwickklung beim Umsatz und Gewinn aufweisen kann. Die Umsätze und Gewinne steigen sage und schreibe seit 73 Jahren ohne ein jahr Unterbrechung, die Dividenden werden seit 44 Jahren jedes Jahr angehoben, in den letzten 10 Jahren im Schnitt um 15% jährlich.

Diese Geschichte drückt sich natürlich an dem gewaltigen Langfristchart aus. Ganz interessant auch, dass das PE-Verhältnis auf historisch niedrigem Stand ist, Dividendenrendite bei aktuell 2,5%. Wachstum für die nächsten 5 jahre bei rd. 11%.

Die Produkte des täglichen Bedarfs kennen insbesondere die damen unter uns, jedoch in JNJ viel breiter aufgestellt, insbesonders im medizinischen Bereich.

Johnson & Johnson istdas weltweit größte Unternehmen im Bereich Health Care mit Sitz in New Brunswick im US-Bundesstaat New Jersey. Global sind rund 110.000 Mitarbeiter in 200 Unternehmen in über 54 Ländern beschäftigt, und ihre Produkte werden in 175 Ländern vertrieben. Die Produktpalette reicht von erfolgreichen Marken für Körper- und Babypflege über Hygieneprodukte und medizinische Kosmetik (z. B. Penaten Creme oder Neutrogena Shampoo) bis hin zu Pharmazeutika, chirurgischer Wundversorgung, Implantaten und minimal invasiven Instrumentarien (z. B. Nizoral, ein Wirkstoff gegen Pilzinfektionen oder Retin-A Micre, eine antibakterielle Gesichtscreme). Viele interessante Medikamente sind in der Pipeline wie z.B. eines für Schuppenflechte.

Ich habe mir heute ne erste Position ins Depot gelegt und mich würde interessieren, on es jemand gibt, der auch investiert ist und einen kleinen Austausch hier starten möchte.

Gruss space


Avatar
22.11.07 21:18:22
Antwort auf Beitrag Nr.: 32.526.671 von spaceistheplace am 22.11.07 16:46:06Heute wieder einer dieser “Ich hasse meinen Job” - Tage?
Kein Problem - es gibt Abhilfe!

Gehe nach Feierabend in eine Apotheke und gehe zu den Fieberthermometern. Kaufe ein Rektalthermometer der Marke “Johnson & Johnson”. Versichere dich, dass es dieser Hersteller ist! Wenn du zu Hause bist, schließe deine Türen ab, stecke dein Telefon aus und stelle die Klingel ab. Du darfst nicht gestört werden! Ziehe dir bequeme Kleidung an und mache es dir in deinem Bett so richtig gemütlich. Jetzt öffne die Packung und nehme das Rektalthermometer zur Hand. Lege es vorsichtig neben dir auf das Bett, so dass es nicht beschädigt wird. Nehme nun die Packungsbeilage aus der Verpackung und lese sie dir durch. Du wirst auf den folgenden Satz stoßen: “Jedes Rektalthermometer der Marke Johnson & Johnson” ist persönlich getestet.” Nun schließe deine Augen und wiederhole diesen Satz fünf mal laut: “Ich bin so glücklich, dass ich nicht in der Qualitätskontrolle bei der Firma “Johnson & Johnson” arbeite!!”. Merke: Es gibt immer irgendwo jemanden, mit einem schlechteren Job als Deinem! :D
Avatar
23.11.07 07:45:07
Antwort auf Beitrag Nr.: 32.530.051 von Borger52 am 22.11.07 21:18:22sorry, aber für solche statements habe ich den Thread nicht geöffnet...
Avatar
29.11.07 08:26:39
HEALTH / VISION CARE

J&J sees potential for contact lens business

PITSINEE JITPLEECHEEP

Johnson & Johnson Vision Care Inc, the optical unit of Johnson & Johnson, has set its sights on expanding its vision-care business in Asia. The maker of Acuvue contact lenses has seen huge growth potential in many emerging markets in Asia, according to Jean Accad, regional vice-president and managing director of Johnson & Johnson Vision Care in Asia Pacific.

He added that Thailand was an important market in Southeast Asia because of the low usage contact lenses relative to its population.

While the penetration rate of contact lenses for vision correction in developed markets such as the United States is as high as 40%, the rates in India and some parts of China are less than 5%.

In Thailand , the rate is estimated at between 10% and 12% in big cities such as Bangkok, while elsewhere in the country it is between 5% and 6%.

Thailand's contact-lens market is estimated to be worth about 1.5 billion baht this year, up 15-20% over last year.

To educate the people about contact lenses, Johnson & Johnson Vision Care set up The Vision Care Institute (TVCI), a non-profit organisation aimed at providing training curricula to ophthalmologists and vision-care practitioners up to the advanced level, said Mr Accad.

The mission of TVCI is to meet the demand of the patients through innovation and education. The institute will also work with the universities and academics in the country where it is located to raise public awareness about the importance of eye care.

Mr Accad said there were now eight TVCI branches worldwide, including one each in Bangkok, Taipei, Seoul, Tokyo and Shanghai. Two more will open in Dubai and Russia next year.

The TVCI in Bangkok, which was opened a year ago, is the centre for Southeast Asia. So far, it has attracted 800 eye-care practitioners, about 600 of whom are from Thailand and the balance from other countries including Malaysia, Singapore, India and the Philippines.

The company expected its TVCI in Bangkok to welcome about 2,000 people next year, about 1,200 of whom will be from Thailand.
Avatar
30.11.07 09:03:05
Laut Focus money ein sehr beliebter Wert bei den US-Valueinvestoren. Bin mal gespannt ob es wirklich nach oben geht oder ob es wieder Richtung 60 USD geht.
Avatar
30.11.07 09:09:33
Antwort auf Beitrag Nr.: 32.623.352 von benny_m am 30.11.07 09:03:05wir befindren uns jetzt am ATH, das schon 2 mal erreicht wurde. kann gut sein, dass es wieder zurück geht, wenn der Widerstand zu groß ist, andersherum ist der weg nach oben frei, wenn er geknackt wird.
Ist heiters Beruferaten. Früher oder später wird er geknackt, weil die Gewinne weiter steigen werden und der Kurs nachfolgen wird.
JNJ ist ein Wachstumsunternehmen, das es von der Bewertung her gar für Value-Leute interessant macht. Solche Situiationen gibts nicht oft!

Gruss space

ier die letzten 5 jahre mit dem Widerstand bei rd. 70 Dollar:



Hier noch news:

Johnson & Johnson to Book $440M Charge
Thursday November 29, 6:06 pm ET
Johnson & Johnson to Book Special $440M Charge Related to Decreased Sales of Heart Drug

NEW YORK (AP) -- Johnson & Johnson expects to record a $440 million one-time charge in the fourth quarter because the company has reduced its future cash flow estimates for NATRECORr, a heart failure drug, according to a regulatory filing Thursday.

ADVERTISEMENT
In the Securities and Exchange Commission filing, the health care products maker said the after-tax, non-cash charge is required to write down the intangible asset related to the treatment.

Despite the recent sales decline that led to the charge, Johnson & Johnson said a subsidiary, Scios Inc., will continue to market NATRECORr.

Johnson & Johnson said the charge will not affect the company's earnings-per-share guidance, which excludes special items.

Johnson & Johnson also reported that it expects to book a special tax gain of about $260 million related to the restructuring of certain international subsidiaries.

The tax gain will also not impact the company's earnings outlook.

Johnson & Johnson shares fell 40 cents to $68 in after-hours trading, after gaining 5 cents to $68.40 during the regular session. Earlier in the day, Johnson & Johnson hit a 52-week high of $68.66.

(This version CORRECTS the amount of the charge.)
Avatar
30.11.07 09:11:48
Ich würde eher sagen man befindet sich in USD seit 3 Jahren in einer Seitwärtsbewegung.

Desweiteren hat J&J ja auch einige Probleme und wird deshalb derzeit nicht höher bewertet.
Avatar
30.11.07 09:21:04
Antwort auf Beitrag Nr.: 32.623.443 von benny_m am 30.11.07 09:11:48Ich würde eher sagen man befindet sich in USD seit 3 Jahren in einer Seitwärtsbewegung.

Und in der gleichen zeit die Gewinne um rd. 40% gesteigert. herrchen/Hund-Prinzip trifft hier auch zu, wobei der Hund klar hinter dem Herrchen her läuft...die Bewertung ist von KGV über 25 auf 18 zurückgekommen.


Desweiteren hat J&J ja auch einige Probleme und wird deshalb derzeit nicht höher bewertet.

Die werden die aber früher oder später lösen, da bin ich mir sicher. Management ist 1A!

Die Qualität des Unternehmens sieht man schon allein in den letzten Wochen, als JNJ der allg. fallenden Börsen steigende Kurse entgegengesetzt hat. Klar kann man da nicht das schnelle geld machen, will ich auch gar nicht. 10-12% pro Jahr plus 2,5% Divi, die jährlich um rd. 15% angehoben wird (zumindest wars in den letzten 10 Jahren so), reicht mir vollkommen. Absolut sicherer tanker, mit dem man alle Krisen durchschiffen kann. Grundsätzlich sollte ein Großteil des Depots in solchen Werten liegen, meiner Meinung nach.

Gruss space
Avatar
30.11.07 09:24:52
J&J hatte auch keine großartigen Kursgewinne abzugeben. Außerdem sind sie ja bei 60 USD durch das Rückkaufprogramm begrenzt.

Außerdem hat Buffets Firma ja ziemlich nachgelegt... was ja auch immer zu steigendem Interesse privater Leute führt... dazu wird derzeit vermutlich in den USA auch einiges in nicht-zyklische Werte umgeschichtet.
Avatar
30.11.07 09:30:31
Antwort auf Beitrag Nr.: 32.623.600 von benny_m am 30.11.07 09:24:52dazu wird derzeit vermutlich in den USA auch einiges in nicht-zyklische Werte umgeschichtet.

Ja, wird auch höchste zeit, denn in Phasen abschwächenden Wirtschaftswachstums sind eben Zykliker vorerst mal out.

Das sagen wir ja im Gewinner-Thread schon lange, dass die großen US-Multis aktuell zu günstigen Preisen zu haben sind.

Gruss space
Avatar
30.11.07 14:09:10
Schöner Artikel der Fools zur Unterbewertung von JNJ:

Mano a Mano Over Johnson & Johnson
By Anders Bylund November 29, 2007

3 Recommendations

One year ago, two Fools traded virtual punches over Johnson & Johnson (NYSE: JNJ). It's time to apply the benefit of hindsight to find out who presented the sounder argument.

Bulls on parade
Steven Mallas traded his jester's cap for a set of bullish horns, in shocked disbelief that anyone would actually take the opposite view.

This is, after all, the very blueprint of a blue chip, a company so large and so well known that introductions are pointless. Working through more than 200 subsidiary operations, J&J is a giant in health care and consumer goods fully on par with Merck (NYSE: MRK) or Pfizer (NYSE: PFE) on the one hand, and Procter & Gamble (NYSE: PG), Kimberly-Clark (NYSE: KMB), or Colgate-Palmolive (NYSE: CL) on the other.

There was a 44-year history of annual dividend growth (45 years now), $50 billion in annual sales, and a most impressive long-term stock chart. "The pharmaceutical industry will be important to baby boomers, as well as to everyone else for an eternal time period," Steven said. "J&J will take advantage of that need. It will reap huge amounts of free cash flow from its drug development and its consumer-products division."

Whip it!
Brian Lawler wielded the bear claws, and the battle was on. Brian agreed that J&J was a great company with a blue-chip pedigree, but he thought the gravy train had reached the end of the growth line.

"Sure, flat operating margins and slow operating-income increases can be forgivable if revenues continue to grow strongly, but sales growth has been anemic in recent years for J&J," he said. Declining sales of drug-coated stents and expiring drug patents spelled more trouble for the company, and with such a massive market cap, it just wasn't realistic to believe in much more growth. And new drug development is such a risky and costly business that you just never know what J&J's future will look like.

Our readers thought Steven had made his point and gave him 71% of 263 votes. Brian had to settle for 19% of the ballots, and 10% remained undecided. That's a landslide bullish victory on the popular vote.

Je t'aime ... moi non plus
Mr. Market tells a different story. The share price went south over the summer, losing nearly 10% of the cap value it sported late last November. A recent rally has brought J&J back into the black, but the stock still hasn't even matched the performance of S&P 500 Spiders (AMEX: SPY) over the last 12 months. We're tied at one-all.

The CAPS community still loves J&J, though. About 95% of more than 5,400 players with an opinion on the stock give it a thumbs-up, and its rating oscillates between four and five stars. A recent re-Duel over the company also showed that a Foolish bull argument still makes sense -- the landslide victory margin turned into a veritable avalanche this time. All in all, this referee has to award the victory to Steven and the bulls. Congrats!

Don't get me wrong
Aside from technicalities like community votes and stock performance, I have to tell you that Johnson & Johnson is a peerless juggernaut of a company that looks more undervalued than stalled today.

The stock's enterprise value trades today at just 21 times trailing-12-months free cash flow. The only time in the past 12 years the stock was available on the cheap like this was when Merck's Vioxx woes dragged the whole sector down in 2004. Otherwise, price-to-cash-flow ratios like to hover around the mid-30s or better.

This massive discount only makes sense if J&J somehow broke in the past couple of years. I don't think it did. In fact, the company looks healthier than ever as baby boomers get set to retire soon. J&J has fortified its consumer products department with a few choice acquisitions, too. I have to agree with Steven: What's not to love?

You might agree -- maybe you don't. Either way, I'd encourage you to mosey on over to Motley Fool CAPS and tell everybody why you feel that way. Click here, rate the stock to taste, and pen a glowing sonnet or scathing diatribe on the company, this article, or the baggage retrieval system they've got at Heathrow -- whatever concerns you the most. It's fun, it's free, and you'll make us all a bit smarter.
Avatar
09.12.07 10:41:13
Pivotal Phase III Data Showed Rivaroxaban Was Statistically Superior to Enoxaparin in Preventing Venous Thromboembolism (VTE) in Patients Following Hip Replacement Surgery
Head-to-Head Study Demonstrated Similar & Low Rates of Major Bleeding for Both Drugs

ATLANTA, Dec 08, 2007 (BUSINESS WIRE) -- Results from a Phase III trial in patients undergoing total hip replacement surgery presented today showed that administration of the oral, once-daily, investigational anticoagulant, rivaroxaban, was statistically superior to once-daily subcutaneous administration of enoxaparin, the current standard of care in preventing venous thromboembolism (VTE) in patients following hip replacement surgery. Rivaroxaban is being jointly developed by Johnson & Johnson Pharmaceutical Research & Development, L.L.C. and Bayer HealthCare AG.

Data from the RECORD1 study show that rivaroxaban demonstrated a 70% relative risk reduction (RRR) (p less than 0.001) in total VTE when compared with enoxaparin, and an 88% RRR (p less than 0.001) in major VTE. Rivaroxaban demonstrated a similar rate of both major bleeding (0.3% and 0.1%, respectively, p=0.178) and non-major bleeding (5.8% and 5.8% p=1.000) compared to enoxaparin.

These data were released today at a press conference during the 49th Annual Meeting of the American Society of Hematology (ASH) by Dr. Bengt Eriksson, Orthopedic Surgeon at the Sahlgrenska University Hospital/Ostra, Gothenburg, Sweden, and Principal Investigator of the RECORD1 clinical trial. In addition, Dr. Eriksson will present the RECORD1 results at the major plenary session on Sunday, December 9th.

Rivaroxaban is a novel, oral, once-daily direct Factor Xa inhibitor in advanced clinical development for a range of patients who could benefit from the prevention and/or treatment of blood clots. Rivaroxaban works at a pivotal stage in the coagulation process to directly inhibit the enzyme Factor Xa.

The RECORD1 (REgulation of Coagulation in major Orthopedic surgery reducing the Risk of DVT and PE) clinical trial evaluated the safety and efficacy of rivaroxaban with enoxaparin in patients undergoing total hip replacement surgery. The duration of thromboprophylaxis in both treatment groups was five weeks. The primary endpoint was total VTE (composite of deep vein thrombosis, non-fatal pulmonary embolism and all-cause mortality) and the main secondary endpoint was major VTE (composite of proximal deep vein thrombosis, non-fatal pulmonary embolism and VTE-related death).

Further Phase III data evaluating rivaroxaban in major orthopedic surgery - including results from the RECORD2 and RECORD3 clinical trials - will be presented during oral sessions on Monday, December 10th at the ASH meeting in Atlanta. The corresponding abstracts (#307 and #308) may be viewed online at the ASH website at www.hematology.org/meetings/abstracts.cfm.

About Rivaroxaban

To date, rivaroxaban is the most studied oral, direct Factor Xa inhibitor in clinical development. More than 20,000 patients have been evaluated in the completed Phase II programs and enrolled thus far in the Phase III programs. Almost 50,000 patients are expected to be evaluated in the total clinical development program.

Bayer HealthCare submitted a regulatory filing to the European Agency for the Evaluation of Medicinal Products (EMEA) at the end of October 2007 for approval to market rivaroxaban in the EU for the prevention of VTE in patients undergoing major orthopedic surgery of the lower limbs. Upon regulatory approval, rivaroxaban will be commercialized in Europe by Bayer Schering Pharma. A filing for rivaroxaban for a similar indication in the United States is planned in 2008, where upon approval, it will be commercialized by Scios Inc. and Ortho-McNeil, Inc., both of which are wholly-owned subsidiaries of Johnson & Johnson.

Johnson & Johnson Pharmaceutical Research and Development

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD), is part of Johnson & Johnson, the world's most broadly based producer of healthcare products. J&JPRD is headquartered in Raritan, NJ, and has facilities throughout Europe and the United States. J&JPRD is leveraging drug discovery and drug development in a variety of therapeutic areas to address unmet medical needs worldwide.

(This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from J&JPRD's expectations and projections. Risks and uncertainties include general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 31, 2006. Copies of this Form 10-K, as well as subsequent filings, are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. J&JPRD does not undertake to update any forward-looking statements as a result of new information or future events or developments.)

SOURCE: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Avatar
12.12.07 15:59:15
12.12.2007 15:43
Johnson & Johnson's schizophrenia treatment shows long-term safety/tolerability

NEW YORK (Thomson Financial) - Johnson&Johnson (Nachrichten/Aktienkurs) Wednesday said its schizophrenia anti-psychotic treatment, Invega extended-release tablets, showed favorable long-term safety and tolerability during a one-year study.

On average, the company-sponsored study found patient symptom scores improved or were stable.

Symptoms of schizophrenia were reduced in patients that transitioned from placebo to Invega and were maintained in those that were previously on Invega.

Discontinuations resulting from treatment-related adverse events were 6%, as were discontinuations resulting from serious treatment-related events.

'This long-term extension trial adds to the body of knowledge regarding the safety of Invega in the longer-term treatment of schizophrenia. The study also suggests that symptom control is maintained over time,' said a principal investigator involved with the 235-patient study.

Shares of the New Brunswick, N.J.-based health care products company closed Tuesday at $67.55.

Melinda Peer
Avatar
17.12.07 08:19:08
JNJ ist eben allerhöchste Qualität:

17.12.2007 06:13
J&J's new 8 bln usd credit facilities assigned 'Aaa' rating - Moody's

MUMBAI (Thomson Financial) - Moody's Investors Service said it has assigned its 'Aaa' rating to Johnson&Johnson's (J&J) new credit facilities totaling 8 bln usd, citing the company's large scale and diversity, its leading market positions and its strong cash flow to debt ratios.

The 'Aaa' rating on J&J's former 5-year credit facility of 1.25 bln usd, which has been replaced with the new credit facilities, is withdrwan, the ratings agency said.

J&J's rating outlook is stable, Moody's said.

TFN.newsdesk@thomson.com

ypv/man

COPYRIGHT
Avatar
22.12.07 11:18:19
Supplemental New Drug Application for PREZISTA(TM) Submitted to U.S. Food and Drug Administration

Additional Data Submitted to FDA for Traditional Approval

Yardley, PA (December 21, 2007) - Tibotec, Inc., today announced it has submitted a Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for the protease inhibitor (PI) PREZISTA(TM)(darunavir), which seeks traditional approval and an expanded indication to include human immunodeficiency virus (HIV)-1-infected, treatment-naïve adults. The application includes 48-week data from two Phase 3 studies, ARTEMIS and TITAN, which were presented at HIV conferences earlier this year, as well as 96-week data from the Phase 2b studies, POWER 1, 2, and 3.

PREZISTA(TM) received accelerated approval in June 2006 based on the 24-week analysis of HIV viral load and CD4+ cell counts from the pooled analysis of the TMC114-C213 (POWER 1) and TMC114-C202 (POWER 2) Phase 2b studies. As part of the post-marketing commitment, 48-week data from ongoing Phase 3 studies (ARTEMIS and TITAN) and 96-week data from POWER 1, 2, and 3 are required before the FDA can consider traditional approval for PREZISTA(TM).

PREZISTA(TM), co-administered with 100 mg ritonavir and with other antiretroviral agents, is currently indicated for the treatment of human immunodeficiency virus (HIV) infection in antiretroviral treatment-experienced adult patients, such as those with HIV-1 strains resistant to more than one protease inhibitor.

This indication is based on Week 24 analyses of plasma HIV RNA levels and CD4+ cell counts from two controlled trials of PREZISTA(TM)/ritonavir (r) in combination with other antiretroviral drugs. Both studies were conducted in clinically advanced, treatment-experienced (NRTIs, NNRTIs, and PIs) adult patients with evidence of HIV-1 replication despite ongoing antiretroviral therapy.

The following points should be considered when initiating therapy with PREZISTA(TM)/r:

* Treatment history and, when available, genotypic or phenotypic testing should guide the use of PREZISTA(TM)/r.
* The use of other active agents with PREZISTA(TM)/r is associated with a greater likelihood of treatment response.
* The risks and benefits of PREZISTA(TM)/r have not been established in treatment-naïve adult patients or pediatric patients.

ARTEMIS

The sNDA submission includes the 48-week efficacy and safety results of ARTEMIS (AntiRetroviral Therapy with TMC114 Examined In naïve Subjects), a Phase 3, randomized, controlled, open-label study that compared the efficacy and safety of PREZISTA(TM)/r with the PI lopinavir/r in treatment-naïve HIV-1-infected adult patients. Patients were randomized to receive a PREZISTA(TM)/r dose of 800 mg/100 mg once daily (an investigational dose) or, based on approved dosing in each country, either lopinavir/r 800 mg/200 mg once daily or 400 mg/100 mg twice daily, plus an optimized background regimen (OBR) of tenofovir and emtricitabine once daily. Data from this study were presented at the 47thInterscience Conference on Antimicrobial Agents and Chemotherapy(ICAAC) in Chicago on September 18, 2007.

TITAN

The sNDA submission also includes data from TITAN (TMC114/r In Treatment-experienced pAtients Naïve to lopinavir/ritonavir), a 96-week, Phase 3, randomized, controlled, open-label study, comparing the efficacy and safety of a PREZISTA(TM)/r dose of 600 mg/100 mg twice daily with lopinavir/r 400 mg/100 mg twice daily, each with OBR, in treatment-experienced HIV-1-infected adult patients who were lopinavir/r-naïve. Forty-eight week data from this study were published in the July 7, 2007, issue of The Lancet and presented at the 4th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention in Sydney, Australia, on July 24, 2007.

Important safety information

PREZISTA(TM) does not cure HIV infection or AIDS, and does not prevent passing HIV to others.

PREZISTA(TM) is contraindicated in patients with known hypersensitivity to any of its ingredients.

Coadministration of PREZISTA(TM)/r is contraindicated with drugs that are highly dependent on CYP3A for clearance and have a narrow therapeutic index (e.g., astemizole, terfenadine, dihydroergotamine, ergonovine, ergotamine, methylergonovine, cisapride, pimozide, midazolam, or triazolam) and for which elevated plasma concentrations are associated with serious and/or life-threatening events. Coadministration is not recommended with carbamazepine, phenobarbital, phenytoin, rifampin, lopinavir/ritonavir, saquinavir, lovastatin, pravastatin, simvastatin, or products containing St. John's wort (Hypericum perforatum).

Caution should be used when prescribing agents such as sildenafil, vardenafil, tadalafil, or other substrates, inhibitors, or inducers of CYP3A in patients receiving PREZISTA(TM)/r. This list of potential drug interactions is not complete.

PREZISTA(TM) must be co-administered with 100 mg ritonavir and food to exert its therapeutic effect. Failure to correctly administer PREZISTA(TM) with ritonavir and food will result in reduced plasma concentration of PREZISTA(TM) that will be insufficient to achieve the desired antiviral effect. Please refer to ritonavir prescribing information for additional information on precautionary measures.

Severe skin rash, including erythema multiforme and Stevens-Johnson Syndrome, has been reported in subjects receiving PREZISTA(TM) during the clinical development program. In some cases, fever and elevations of transaminases have also been reported. In clinical trials (n=924), rash (all grades, regardless of causality) occurred in seven percent of subjects treated with PREZISTA(TM); discontinuation due to rash was 0.3 percent. Rashes were generally mild-to-moderate, self-limiting and maculopapular. PREZISTA(TM) should be discontinued if severe rash develops.

PREZISTA(TM) should be used with caution in patients with known sulfonamide allergy.

New-onset or exacerbations of pre-existing diabetes mellitus and hyperglycemia, and increased bleeding in hemophiliacs have been reported in patients receiving protease inhibitors. A causal relationship between protease inhibitors and these events has not been established.

PREZISTA(TM) should be used with caution in patients with hepatic impairment. There are no data regarding the use of PREZISTA(TM) in patients with varying degrees of hepatic impairment; therefore, specific dosage recommendations cannot be made.

Redistribution and/or accumulation of body fat have been observed in patients receiving ARV therapy. The causal relationship, mechanism, and long-term consequences of these events have not been established.

Immune reconstitution syndrome has been reported in patients treated with ARV therapy.

The potential for HIV-cross-resistance among protease inhibitors has not been fully explored in PREZISTA(TM)/r treated patients.

PREZISTA(TM) should be used during pregnancy only if the potential benefit justifies the potential risk. There are no adequate and well-controlled studies in pregnant women. The effects of PREZISTA(TM) on pregnant women or their unborn babies are not known.

In the pooled analysis of POWER 1 and 2 studies, the most frequently reported drug-related adverse events of at least moderate to severe intensity in patients receiving PREZISTA(TM)/r-containing regimen were headache (3.8 percent), diarrhea (2.3 percent), abdominal pain (2.3 percent), constipation (2.3 percent), and vomiting (1.5 percent).

Please see full Prescribing Information for more details. A copy of full Prescribing Information can be obtained by visiting PREZISTA.com.

About Tibotec, Inc.

Tibotec, Inc., based in Yardley, Pa., is a pharmaceutical research and development company, with headquarters in Ireland and an operating affiliate in Belgium. Tibotec Inc., is dedicated to the discovery and development of novel, new drugs for HIV/AIDS and other infectious diseases.

About Tibotec Therapeutics

Tibotec Therapeutics, a division of Ortho Biotech Products, L.P., headquartered in Bridgewater, N.J., is dedicated to delivering innovative virology therapeutics that help healthcare professionals address serious unmet needs in people living with HIV.
Avatar
27.12.07 17:02:09
JOHNSON & JOHNSON steht seit kurzem auch ganz oben auf meiner Watchlist, die Aktie kenne ich zwar schon lange aber bisher hab ich nie ernsthaft nen Kauf in Erwägung gezogen.
Warum weiß ich selbst nicht genau - hauptsächlich weil ich mit Blick auf das KGV und das Wachstum der nächsten Jahre ne Überbewertung zu sehen glaubte.
Aber vor dem 01.01.2009 ist ein Kauf eigentlich ein Muss, die Frage ist nur wann.
Avatar
27.12.07 17:23:30
Antwort auf Beitrag Nr.: 32.880.679 von 1435905 am 27.12.07 17:02:09Habe den Wert zwar auch im Blick, aber Fakt bleibt, wer vor 8 Jahren diesen sogenannten konservativen Wachstumswert gekauft hätte, der hätte nur eine Nettodividende von ca. 1,5% pro Jahr erzielt.

Auf Euro Basis natürlich obige Darstellung.

Mmh, das ist ja nicht mal die Inflationsrate gewesen.
Avatar
27.12.07 18:20:51
Antwort auf Beitrag Nr.: 32.880.679 von 1435905 am 27.12.07 17:02:09ich würde dir empfehlen deine investition auf mehrere Käufe zu verteilen
Avatar
28.12.07 10:00:14
Habe den Wert zwar auch im Blick, aber Fakt bleibt, wer vor 8 Jahren diesen sogenannten konservativen Wachstumswert gekauft hätte, der hätte nur eine Nettodividende von ca. 1,5% pro Jahr erzielt.

Auf Euro Basis natürlich obige Darstellung.

Mmh, das ist ja nicht mal die Inflationsrate gewesen.


das ist zwar richtig aber man sollte auch erwähnen das jnj damals mit einem kgv von über 40 extrem überbewertet war. das unternehmen wuchs die ganze zeit kontinuierlich in dem bereich des seit jahrzehnten vorhandenen wachstums weiter und notiert jetzt mit einem 15er kgv in anbetracht der qualität und des nachhaltigen wachstums sehr günstig

ebenfalls sollte man erwähnen das der € in den letzten 5 jahren phatastisch performte und deswegen eine in dollar notierte aktie dagegen zu kämpfen hat. Die währungstrends dürften sich aber am ändern sein so das wir in den nächsten jahren bei jnj die günstige situation eines steigenden aktienkurses bei gleichzeitig gegenüber dem € zulegenden dollar erleben werden.


JNJ STrong buy

das unternehmen steigert seit über 70 jahren in folge gewinn umsatz und dividende
Avatar
28.12.07 11:13:06
Antwort auf Beitrag Nr.: 32.885.409 von Pontiuspilatus am 28.12.07 10:00:14dem bleibt nix hinzuzufügen! Wer da nicht kauft, ist selber schuld! JNJ gehört in jedes Langfristdepot!

Gruss space
Avatar
28.12.07 11:52:18
Antwort auf Beitrag Nr.: 32.885.409 von Pontiuspilatus am 28.12.07 10:00:14warum soll der Dollar steigen?

Weil er zu steigen hat oder gibt es Gründe dafür?
Avatar
28.12.07 15:45:10
Antwort auf Beitrag Nr.: 32.886.336 von Schürger am 28.12.07 11:52:18zu$:
Wegen Annäherung an die Kaufkraftparität, mMn.
Avatar
29.12.07 15:44:47
Antwort auf Beitrag Nr.: 32.888.406 von Simonswald am 28.12.07 15:45:10so ist die Theorie
Avatar
29.12.07 16:07:10
so ist die Theorie

nö das ist langfristig immer das was eintritt.

wenn die marktteilnehmer auf markt a das gleiche 30 % günstiger bekomme als auf markt b dann wird die nachfrage zunehmend dorthin fliessen wo man mehr fürs geld bekommt.

in den usa ist der kaufkraftvorteil gegenüber dem € inzwischen riesig.
ich dage nicht das der $ nicht weiter gegenüber anderen währungen (vor allem emerging markets ) sehr viel an wert verlieren wird aber dies gilt noch mehr für den € der gegenüber diesen währungen noch stärker überbewertet ist.

es gibt keine real existenten gründe die einen gegenüber dem € dauerhaft schwächber gehenden $ rechtfertigen würden.

oft wird das handelsbilanzdefizit angeführt.
dazu ist zu sagen das hier erstens keine korrelation zwischen handelsbilanzdefizit und wechselkursen besteht und sogar wenn solch ein korrelativer zusammenhang bestünde möchte ich vorsorglich darauf hinweisen , das die handelsbilanz zwischen eu und usa nicht sehr negativ sondern seit jahrzehnten innerhalb der gleichen relationen schwankt
es ist ebenfallls zu erwähnen das man wenn schon die ganze leistumgsbilanz betrachten muss (Handels, kapitals, dienstleistungsbilanz usw...) und sich dann keinerlei vorteil für eu ergibt.

man muss sich nur ansehen wie sich die großen kapitalverkehrsströme richtung usa umzuorientieren beginnen da die marktteilnehmer erkenn das es dort mehr fürs geld gibt (siehe z.b die steigende übernahmetätigkeit von eu firmen in usa usw.)

das einzige was währungen beiinflusst ist das zinsniveau da in den usa die zinsen sinken und in eu noch nicht verliert der $, das geht jedoch nicht ewig so weiter. historisch gesehen dauern währungstrend regelmäßig ca 5- 7 jahren. Nächstes jahr dürfte ein gutes $ jahr werden.(ausnahme würde ich für den fall einer sich massiv verschärfenden kreditkrise machen dann kann der sicher noch mal 10-15 % verlieren, was aber nichts daran ändern wird das langfristig wieder die kaufkraftparität angesteuert werden wird )

$ € stehen auch mal wieder bei 1:1. ich weiss das glaubt jetzt keiner aber abwarten jungs ;)
Avatar
31.12.07 02:24:13
Antwort auf Beitrag Nr.: 32.894.501 von Pontiuspilatus am 29.12.07 16:07:10@pontius:

Versuch doch bitte mal Kontakt zu den Devisenhändlern der Großbanken herzustellen.:D
Dein Tipp könnte denen viele Mio Gewinn einbringen!
Avatar
31.12.07 02:52:47
Antwort auf Beitrag Nr.: 32.894.501 von Pontiuspilatus am 29.12.07 16:07:10gilt noch mehr für den € der gegenüber diesen währungen noch stärker überbewertet ist
Du meinst diese ganzen Schwellenländerwährungen, vermute ich? Auch die Rupie?
Avatar
31.12.07 12:44:08
Versuch doch bitte mal Kontakt zu den Devisenhändlern der Großbanken herzustellen

die folgen dem trend auch wenn sie wissen das der € fundamental bei weitem überbewertet ist.

Du meinst diese ganzen Schwellenländerwährungen, vermute ich? Auch die Rupie?

ja alle emerging markets die in relation zu den etablierten industrieländern an wirtschaftskraft gewinnen werden auch gegenüber deren währungen zwangsläufig aufwerten.

die tatsache das viele dieser länder dies künstlich zu verhindern suchen ist verantwortlich für die ungleichgewichte zwischen usa und diesen ländern und auch für die explosionsartig wachsenden ungleichgewichte zwischen europa und den emerging markets.

im vergleich zwischen eu und usa ist eu aufgrund vieler faftoren die strukturell schwächer werdende wirtschaft obwohl eu eine super infrastruktur, bildung und kultur hat wird dieses nicht effizient eingesetzt. die wirklich langfristigen trends sprechen so was von eindeutig gegen den € das es wehtut. ich denke spätestens ab 2010 wird es offensichtlich werden.

probleme der usa wie kredit immobilienkrise usw sind kurz bis mittelfristiger natur (dämpfen das wachstum und sind vielleicht sogar von den gruppen die in den usa die fäden ziehen gewollt um spekulative übertreibungen abzubauen) dürften aber nicht länger als 5 jahre wirken. In den eu ländern higegen sehen wir gravierende strukturverschiebungen vor alllem aufgrund der bevölkerungsentwicklung und der verschiebung des gesellschaftlichen aufbaus welche unser gesamtes leben nicht mehr abänderbar sein werden.

deswegen in europa vor allem auf die staaten setzen die langfristig stabil sind und sonderwege gehen. ich denke hier vor allem an den skandinavischen raum insbesondere norwegen , GB und die schweiz.
diese länder sind sowohl politisch als auch ökonomisch am besten für die kommende umbruchszeit gerüstet.

Für deutschland dürfte der noch andauernde wirtschaftsboom als von der regierung verpasste erkannt werden. diese fehler werden sich in ein paar jahren massivst rächen
Avatar
01.01.08 17:56:01
Antwort auf Beitrag Nr.: 32.904.182 von Pontiuspilatus am 31.12.07 12:44:08von den gruppen die in den usa die fäden ziehen
Achtung Verschwörungstheorie! ;)
Ganz so abwegig ist das nicht mit den einflussreichen Gruppen. Sind halt die Netzwerke, die sich aus Harvard, Yale, Princeton oder Stanford kennen.
Avatar
02.01.08 11:06:30
Achtung Verschwörungstheorie! Zwinkern
Ganz so abwegig ist das nicht mit den einflussreichen Gruppen. Sind halt die Netzwerke, die sich aus Harvard, Yale, Princeton oder Stanford kennen.


nö das hat relativ wenig mit verschwörungstheorie zu tun. das ist die hochfinanz und einflussreiche gesellschaftliche institutionen wie kirchen usw.

die politiker jedenfalls sind nicht die wahren entscheider sondern verkaufen dem volk nur das was es hören soll. Und die breite masse ist sowieso grenzenlos dumm. was im übrigen für alle staaten gilt.
Avatar
02.01.08 11:08:41
Es ist ja sogar so das bspw. die hässliche physikerin aus ossiland behaupten kann die steuerng gesenkt zu haben obwohl es nie größere steuererhöhungen gab.

Und es gibt keinen aufschrei.

die sollte ausreichend beweis dafür sein das die menschen dumm sind;)
Avatar
02.01.08 11:16:06
wobei dem volk als notwendigkeit steigender staatseinnahmen immer soziale gerechtigkeit als totschlagargument präsentiert wird.
de facto kann der staat dieses ziel falls es überhaupt ein sinnvolles ziel sein sollte ( ich denke eher es ist eher eine manie welche ohne groß darüber nachzudenken allgemein akzeptiert ist so das man wenn man dies ablehnt als irrer angesehen wir) nicht erreichen.

es ist sogar so das trotz zunehmender bürokratisierung, steigender steuer und abgeabenlasten usw. usw. die sozialen unterschiede immer mehr zunehmen.

daraus lässt sich gut erkenne das steigende staatseinnahmen in keinem kausalen zusammenhang mit sozialer gerechtigkeit stehen.

die dem volk vom staatsaparat aufgebürdeten kosten haben eher den zweck die aufgeblähten und verfilzten korrupten strukturen in sozialkassen und politik zu finanzieren.

d.h das volk finanziert diejenigen welche seine handlungsfreiheit immer mehr einschränken und dies damt begründen das man nur das beste für das volk will.

Wie gesagt die menschensind dumm;)
Avatar
07.01.08 08:05:19
Guten Morgen zusammen,

hier mal geschwind ne Analomeinung, die aber genau das sagt, was wir schon lange wissen. JNJ ist ein Feld in der Brandung.

Gruss space

04.01.2008 20:35
Johnson & Johnson: Sicherer Hafen - sagt die UBS
New Brunswick, New Jersey (BoerseGo.de) - Der Pharmariese Johnson&Johnson (News/Aktienkurs) ist einer den wenigen, die sich dem Abwärtssog entziehen können. Dazu trägt die UBS (News/Aktienkurs) bei. Die Schweizer starten die Beobachtung mit „Kaufen“ und Kursziel 77 Dollar. Als einer der am breitesten diversifizierten US-Gesundheitskonzerne sei der Pillenhersteller ein „sicherer Hafen“ heißt es dort. Zwar rechne die UBS mit fallenden Umsätzen in diesem und im kommenden Jahr, weil wichtige Patente auslaufen, aber ab 2009 sollte die vielversprechende Pipeline an neuen Präparaten wieder für Wachstum sorgen.

Der Dow-Titel gewinnt 0,55% auf 66,29 Dollar.
Avatar
08.01.08 07:58:38
Avatar
11.01.08 07:48:35
10.01.2008 19:37
FDA sets February meeting for J&J drug

WASHINGTON (AP) - Government advisers will meet in late February to review Johnson&Johnson's antibiotic to treat skin infections.

The Food and Drug Administration's panel of outside antibiotic experts will consider approval of the company's ceftobiprole at a Feb. 28 meeting, according to a notice posted to the agency's Web site. The FDA is not required to follow the panel's recommendations, though it often does.

Shares of Johnson&Johnson (News/Aktienkurs) were flat at $67.8o in afternoon trading.

Copyright 2007 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Avatar
21.01.08 07:58:37
20.01.2008 22:37
Johnson & Johnson says unit's HIV drug granted FDA accelerated approval

LONDON (Thomson Financial) - Johnson&Johnson (News/Aktienkurs) said the US Food and Drug has granted accelerated approval to the anti-HIV medication Intelence tablets, developed by Johnson&Johnson unit Tibotec, a division of Ortho Biotech Products LP.

The drug is used as part of HIV combination therapy, Johnson&Johnson said.

FDA accelerated approval procedures allow for earlier approval of drugs

that provide a meaningful therapeutic benefit over existing treatment for

serious or life-threatening diseases.

tf.TFN-Europe_newsdesk@thomson.com

vs
Avatar
23.01.08 08:57:45
der Vollständigkeite halber:


J&J 4Q Profit Rises; Revenue Climbs
By LINDA A. JOHNSON
Font Scale:
Posted 22 January 2008 @ 01:07 pm EST

* IBTimes RSS
* Print
* E-Mail
* digg
* Del.icio.us

TRENTON, N.J. (AP) - Health care products maker Johnson & Johnson's profit rose almost 10 percent in the fourth quarter as revenues jumped by double digits despite sales drops for two key product lines.

Article Tags
4q climbs profit revenue rises

* Merrill Takes $11.5 Bln Write-Down
* IBM's Strong 4Q Results Boost Tech Sector
* Bank of America 4Q Profit Plunges

More News Related to 4q >>

* Meredith 2Q Profit Climbs on Publishing
* Dollar Climbs Against Euro
* Ark. Unemployment Rate Climbs

More News Related to climbs >>

* Coca-Cola Enterprises boosts 2007 profit estimate
* Cisco Eanings Jump, Shares Slide on Outlook
* Expedia third-quarter profit gains on bookings

More News Related to profit >>

* GE Profit Meets Expectations
* Wesfarmers-Coles combined revenue seen at $39 bln

More News Related to revenue >>

* Oil rises on weaker dollar, OPEC
* Frontier Airlines traffic rises 22Pct.
* Berkshire Profit Rises 64pct

More News Related to rises >>

The New Brunswick, N.J.-based maker of prescription drugs, medical devices, contact lenses and baby care items on Tuesday reported net income of $2.37 billion, or 82 cents per share, up from $2.17 billion, or 74 cents per share, a year earlier. Excluding one-time items, net income would have been 88 cents per share.

Revenues totaled $15.96 billion, up 16.6 percent from $13.7 billion in the year-ago quarter. Most growth came overseas, with international sales jumping 26 percent and currency exchange rates boosting revenues nearly 5 percent.

"This is as good as it gets for them, and it is not a harbinger for good times in the future," said analyst Steve Brozak of WBB Securities.

Analysts surveyed by Thomson Financial were expecting earnings of 86 cents per share excluding one-time items on revenues of $15.4 billion.

"In 2007, we delivered strong results across our broad base of businesses and exceeded expectations," Chief Executive Officer Bill Weldon told analysts at a meeting. "We achieved those results despite having to work through one of the more difficult years in Johnson & Johnson's history."

Last July, the company announced its biggest restructuring ever, saying it would cut up to 4 percent of jobs due to looming patent expirations for key drugs and continuing sales declines for two top products. Anemia treatment Procrit J&J's No. 1 drug until 2005 saw sales fall 20 percent to $628 million in the fourth quarter. In the same quarter, sales fell nearly one-third to $415 million for Cypher, a metal-mesh tube, or stent, that slowly releases medicine to keep a heart artery open after a blockage is cleared.

Brozak said he expects Procrit sales to continue to fall and doesn't see "the stent business getting better."

In the fourth quarter, sales for J&J's medical devices and diagnostics business rose 11 percent, to $5.8 billion, while prescription drug sales rose 7.5 percent to $6.4 billion. Sales of consumer health products such skin and dental products and nonprescription medicines hit $3.8 billion, up 48 percent, mainly due to the December 2006 acquisition of Pfizer Inc.'s consumer health business.

J&J said it expects earnings per share for 2008 to total $4.39 to $4.44, excluding one-time items. Analysts have been looking for earnings of $4.42 a share for 2008.
Avatar
04.02.08 14:40:07
04.02.2008 14:22
FDA to review J&J psoriasis drug
Private Equity boomt!
16% p.a. seit 50 Jahren! 7% Sofortrente! Hohe Renditen bei breiter Risikostreuung!
Top Steuersparmodell
Steuern sparen mit Denkmal Immobilien: Bis zu 90% des Kaufpreises abschreibbar!
Welcher Typ sind Sie?
Für jeden Anlage-Typ das passende Produkt von AKZENT Invest. Machen auch Sie mehr aus Ihrem Geld.

HORSHAM, Pa. (AP) - Johnson&Johnson's subsidiary Centocor Inc. said Monday the Food and Drug Administration will review its application for experimental drug CNTO 1275 for the treatment of psoriasis, a skin disease.

Centocor is seeking approval for the late-stage drug, also known as ustekinumab, to treat adults with chronic moderate-to-severe plaque psoriasis, which results from the overproduction of skin cells and causes red, scaly plaques that itch and bleed.

Centocor discovered ustekinumab and holds exclusive marketing rights to the product in the United States. Janssen-Cilag International NV has exclusive marketing rights in countries outside of the United States.

Copyright 2007 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Avatar
18.02.08 13:47:42
interessant:


Johnson & Johnson Pharmaceutical Pipeline Review
posted on: February 18, 2008 | about stocks: JNJ
Print Email

Dow component Johnson & Johnson Inc. (NYSE: JNJ) recently reported 4Q07 earnings of $0.88 and FY07 EPS of $4.15, a 10% increase from 2006 and $0.02 above analysts estimates (see conference call transcript). I will take this time to provide you with an overview of the company's pharmaceutical portfolio and its outlook for FY08.

In 2007, pharmaceutical sales increased 4% overall (6% ex-US).

Existing Drugs

1) Topamax - Strong 2007 performer, approval for epilepsy treatment in 2007, boost from usage as migraine prevention, mostly US, generic competition in 2009?

2) Levaquin - Strong 2007 performer, growth in international sales buoyed 2007 revenues, increased competition in the US

3) Risperdal (Consta and Invega) - Strong 2007 performer, but older version hurt by generic competition in international markets, patent being challenged by generics in US.

4) Remicade - Strong 2007 performer, increased competition
from other biologics, strong international growth

5) Aciphex - Strong 2007 performer, patent being challenged by generics

6) Concerta - Strong 2007 performer, possible generic in the wings as JNJ asks FDA for clinical trials

7) Velcade - Strong 2007 performer, pending EU approval for use on multiple myeloma

8) Eprex/Procrit - 12% decline in revenue, safety concerns, competition (Amgen/Aranesp), competition in Europe (Roche/Mircera), Medicare restrictions

9) Duragesic - generic competition started in 2007

10) Ultracet - generic competition started in 2007

11) Sporanox - generic competition started in 2007

12) Ortho Tri-Cyclen - huge competition for oral contraceptives, patent being challenged by generics

13) Razadyne - patent being challenged by generics

Drug Pipeline

1) Doribax - approved in October 2007 for UTIs, pending for pneumonia, and on all accounts in EU

2) Intelence - HIV/AIDS drug approved this month

3) A schizophrenia drug coming online possible Fall 2008

4) Depoxetene in Europe for premature ejaculation, possible 2008 market date

5) Cefpobritole for complicated skin infections and pneumonia, possible 2008 market date

6) A drug for plaque psoriasis, possible 2008 market date

7) Tapentadol filing for approval in 2008

8) Rivaroxaban for knee and hip replacement patients filing in 2008

9) A drug to treat RA , filing for approval in 2008

10) Telaprevir for hep C, filing for approval in 2010

11) An oral factor Xa inhibitor strong Phase III results

Feel free to post updates or corrections.
Avatar
21.02.08 13:23:50
schöner Artikel zu JNJ:

Johnson & Johnson: Doubling Its Dividend Every 5 Years

http://seekingalpha.com/article/65466-johnson-johnson-doubli…
Avatar
27.02.08 08:09:14
hört sich nicht so doll an:

Amgen, J&J Anemia Drugs Have Blood Clot, Death Risk - Study2-26-08 4:15 PM EST | E-mail Article | Print Article

WASHINGTON -(Dow Jones)- An analysis of about 50 studies involving Amgen Inc.'s (AMGN) and Johnson & Johnson (JNJ)'s anti-anemia drugs suggests the products are associated with an increased risk of death and blood clots.
The analysis, which is being published in this week's Journal of the American Medical Association, looked at 51 Phase III clinical studies involving Aranesp, Epogen and Procrit in patients with cancer and comes amid an ongoing safety review of the drugs by the U.S. Food and Drug Administration. Phase III studies are advanced clinical studies that are typically conducted to support FDA approval of products.

Previous studies have suggested the drugs increase the risk of blood clots and the drugs' labels already warn of that risk, while certain individual studies of the drugs in cancer patients have suggested the drugs might shorten overall survival.

Twice last year, the FDA updated the drugs' labels to warn of safety problems and the agency will be convening its outside advisory panel of cancer experts on March 13 to discuss two additional studies involving cancer patients that have come out since November. The agency has said it "may take" additional regulatory action involving the drugs but, for now, it has advised patients and doctors to discuss the benefits and risks of the products before deciding whether to use them.

The analysis, led by Charles L. Bennett, an oncologist and medical professor at Northwestern University, looked at 51 clinical trials with 13,611 patients to examine survival. Overall, the analysis showed patients being treated with the drugs had about a 10% higher risk of dying than patients not receiving the drugs, a finding Bennett said was "statistically significant." The risk of venous thromboembolism, or blood clots, was looked at in 38 studies that included 8,172 patients. Overall, those studies found an increased blood-clot risk of 57% among patients receiving the anti-anemia drugs.

"These risks have been previously defined," said Roger Perlmutter, Amgen's executive vice president of research and development. "There are benefits associated with use of these drugs and there are risks."

Amgen makes all three anti-anemia drugs, and Procrit is marketed by Ortho Biotech, a Johnson & Johnson unit, under a license agreement with Amgen. The drugs treat anemia by boosting the number of red-blood cells and are used to treat patients with kidney disease and certain cancer patients receiving chemotherapy. The drugs have been successful at helping patients avoid blood transfusions, which are necessary to boost red-blood cell levels that fall too low. The products fall into a class of drugs known as erythropoiesis-stimulating agents, or ESAs.

Bennett said more research is needed to look at the drugs' impact on tumors, noting that some studies have shown faster tumor growth, in order to figure out which patients should or shouldn't receive treatment with the drugs. Other research has suggested that the same mechanism the drugs use to boost red-blood cell counts could also fuel tumor growth.

-By Jennifer Corbett Dooren, Dow Jones Newswires; 202-862-9294; jennifer.corbett@dowjones.com

(END) Dow Jones Newswires
02-26-081615ET
Copyright (c) 2008 Dow Jones & Company, Inc.
Avatar
27.03.08 08:48:20
Guten Morgen miteinander,

will mich mal melden, denn ich habe Euch was mitzuteilen:

Ich werde mich ab sofort aus WO und aus dem ganzen Börsengeschehen mehr oder minder zurückziehen. Ich habe mir das schon länger überlegt und bin jetzt über Ostern zu diesem Schluss gekommen.

Ich habe gestern fast komplett meinen Aktienbestand verkloppt. Ich habe mit meiner Bank, bei der ich einen Kredit über unser Haus laufen habe, ein große Sondertilgung vereinbart und werde diese in diesen Tagen durchführen. Da fließt das Geld hinein. Lieber meinen Kredit tilgen bzw. abbezahlen als auf im Endeffekt höhere Renditen am Markt spekulieren. Das kann böse in die Hose gehen bzw. ich denke, das eben die Renditen an den Märkten in den nächsten jahren nicht zum Himmel wachsen. Nummer Sicher, fertig...

Ein sehr kleiner Rest ist noch nicht über die Spekufrist (sind aber eh keine großen Gewinne drauf), warte diese aber ab. Bis Ende des Jahres wird dann der Rest des Kredites abbezahlt.

Zudem bin ich auch zum Schluss gekommen, hier bei WO meine Aktivitäten einzustellen. Ich hatte ja schon öfters geschrieben, dass ich zu viel Zeit aufwende und dann doch immer wieder in die gleiche Schiene verfallen bin, einfach zu viel Zeit dafür aufzuwenden, oft auch einfach zu verbissen war, was ich als nicht gut empfinde. Daher werde ich jetzt komplett aufhören und mich auch abmelden, sonst wird das wieder nix.

Also macht es gut, haltet den Thread auch ohne mich als Threadgrünmder warm…
Liebe Grüße an alle
space
Avatar
11.04.08 17:57:49
San Diego, California (ots/PRNewswire) -

- Newly Established Organization Presents Data on Advancing
Compounds at AACR -

Ortho Biotech Oncology Research & Development (ORD), a unit of
Johnson & Johnson Pharmaceutical Research & Development, L.L.C., will
announce results from studies of three innovative compounds--Hdm2,
c-Met, and HDAC inhibitors --here at the American Association for
Cancer Research (AACR) 2008 Annual Meeting.

ORD is a new research and development organization that unites
the biotechnology and pharmaceutical oncology efforts of several
Johnson & Johnson companies with the goal of transforming cancer into
a chronic or curable disease, said William Hait, M.D., Senior Vice
President and Worldwide Head of Ortho Biotech Oncology Research &
Development. The new organization harnesses broad,
multi-disciplinary capabilities and expertise in order to prioritize
existing and emerging opportunities, align cancer treatment with
modern cancer biology and improve patients' lives.

ORD's scientific approach to cancer examines the cancer cell and
the surrounding tissue, or microenvironment. Previously, researchers
often studied cancer as collections of malignant cells growing in
isolation, but now understand cancer cells depend on interactions
with the surrounding tissue to survive, grow and metastasize. ORD
seeks to identify compounds which can inhibit or block the
interaction cancer cells have with the surrounding tissues, which
compromises the cancer's ability to survive.

The organization will combine the microenvironment disruptive
agents (MDAs) resulting from this approach with classic treatments
that directly target cancer cells. MDAs represent one of the most
promising areas of drug discovery, and ORD has a pipeline of several
investigational MDAs, including some of which are first-in-class and
first-in-clinic.

Pre-clinical data presented at this year's AACR meeting
demonstrate evidence of broad-spectrum, anti-tumor activity for three
new compounds. These compounds selectively target specific pathways
and influence the interaction between cancer cells and the
microenvironment to induce cancer cell death. The presentations
include:

- JNJ-26854165, a first-in-class, first-in-clinic Hdm2 inhibitor
which induces apoptosis (programmed cell death) in a number of cancer
cell lines, and restores function of the p53 tumor suppressor protein
through a novel mechanism of action; the compound is in phase I
studies for non-small cell lung cancer and prostate cancer. (Oral
abstract #1592)

- JNJ-26481585, a novel, second-generation pan-Histone
Deacetylase (HDAC) inhibitor with anti-tumor activity against solid
and hematological malignancies, which interferes with expression of
genes that control cancer cell proliferation, angiogenesis and
metastasis; phase I trials are ongoing. (Oral abstract #2444)

- JNJ-38877605, a small molecule that selectively and potently
inhibits the c-Met receptor tyrosine kinase (c-Met RTK) pathway that
regulates inhibition of signaling from the microenvironment to block
cancer cell development and metastasis; based on promising
pre-clinical properties and clean toxicity profile of JNJ-38877605,
ORD has advanced this potent and uniquely selective c-Met inhibitor
into clinical evaluation in multiple metastasized malignancies.
(Poster abstract #4837)

These new agents are just a few of the novel compounds from our
pipeline that we hope may lead to the control of cancer, Dr. Hait
said. The scientific community is attempting to identify all the
genetic abnormalities within cancer cells; this has yielded a finite
number of treatment opportunities. The scientific approach of ORD has
the potential to generate new opportunities to improve cancer care.

About Our Compound Targets

Human Double Minute 2 (Hdm2)

The Hdm2 oncogene is activated in cancers through various
mechanisms, including gene amplification and deletion of upstream
tumor suppressors. Hdm2 over-expression induces tumor formation, and
Hdm2 levels correlate with sporadic tumor incidence in humans(i).
Hdm2 promotes tumor cell proliferation by associating with cell cycle
regulatory proteins, modulating their activity and stability. Key
examples include p53, p73, E2F1 and HIF1a(ii),(iii). This positions
the Hdm2 protein as an attractive target for the development of
anti-cancer agents.

Histone Deacetylase (HDAC)

DNA in chromatin is wound around proteins called histones. HDACs
are a family of enzymes that influence gene expression through
selective regulation of chromatin structure. Inappropriate gene
expressions, due to changes in chromatin structure, are a hallmark of
cancer. HDAC inhibitors aim to normalize chromatin structure, thereby
restoring the activity of genes which inhibit proliferation,
angiogenesis and metastasis(iv).

c-Met Receptor Tyrosine Kinase (c-Met RTK)

Receptor tyrosine kinases (RTKs) are cell surface receptors that
regulate many key processes including invasive growth and cell
survival. The c-Met RTK pathway has been shown to be specifically
important in regulation of cell migration and invasion, cell
proliferation, survival and angiogenesis. Deregulation of c-Met RTKs
has been implicated in the development and progression of numerous
human cancers. The c-Met RTK inhibitors prevent receptor activation
and thus inhibit tumor cell development and
metastasis(v),(vi),(vii),(viii).

About ORD

Ortho Biotech Oncology Research & Development (ORD) is a new
research and development organization dedicated to oncology,
hematology and supportive care. ORD partners closely with Ortho
Biotech Products, L.P. and Janssen-Cilag companies worldwide to bring
oncology treatments and supportive medicines to patients around the
world. ORD is headquartered in Raritan, N.J., and has facilities
throughout Europe and the United States.

(This press release contains forward-looking statements as
defined in the Private Securities Litigation Reform Act of 1995.
These statements are based on current expectations of future events.
If underlying assumptions prove inaccurate or unknown risks or
uncertainties materialize, actual results could vary materially from
the Company's expectations and projections. Risks and uncertainties
include general industry conditions and competition; economic
conditions, such as interest rate and currency exchange rate
fluctuations; technological advances and patents attained by
competitors; challenges inherent in new product development,
including obtaining regulatory approvals; domestic and foreign health
care reforms and governmental laws and regulations; and trends toward
health care cost containment. A further list and description of these
risks, uncertainties and other factors can be found in Exhibit 99 of
Johnson & Johnson's Annual Report on Form 10-K for the fiscal year
ended December 30, 2007. Copies of this Form 10-K, as well as
subsequent filings, are available online at http://www.sec.gov,
http://www.jnj.com or on request from Johnson & Johnson. Johnson &
Johnson does not undertake to update any forward-looking statements
as a result of new information or future events or developments.)

(i) Bond GL, Hu WW, Bond EE, Robins H, Lutzker SG, Arva NC,
Bargonetti J, Bartel F, Taubert H, Wuerl P, Onel K, Yip L, Hwang SJ,
Strong LC, Lozano G, Levine AJ. A Single Nucleotide Polymorphism in
the MDM2 Promoter Attenuates the p53 Tumour Suppressor Pathway and
Accelerates Tumour Formation in Humans. Cell; 2004; 119: 591-602.

(ii) Levine, A J; Hu, W; Feng, Z. The P53 pathway: what questions
remain to be explored? Cell Death and Differentiation; 2006, 13(6),
1027-1036.

(iii) Toledo F, Wahl GM. MDM2 and MDM4: p53 regulators as targets
in anticancer therapy. International Journal of Biochemistry & Cell
Biology; 2007, 39(7-8):1476-82.

(iv) Johnstone, RW. Histone deacetylase inhibitors: novel drugs
for the treatment of cancer. Nature Reviews Drug Discovery; 2002, 1,
287 - 299.

(v) Lesko, E and Majka, M. The biological role of HGF-MET axis in
tumor growth and developmentof metastasis. Fron Biooscie; 2008, 13:
1271-80.

(vi) Sattler, M and Salgia R. c-Met and hepatocyte growth factor;
potential as novel targets in cancer theray. Curr Oncol Rep; 2007, 9
(2) 102-8.

(vii) Boccaccio C, and Comoglio, PM. Invasive growth; a MET
driven genetic programme for cancer and stem cells. Nat Rev Cancer;
2007, 6(8) 637-45.

(viii) Peruzzi, B and Bottaro, DP. Targeting the c-Met signaling
pathway in cancer. Clin Cancer Res; 2006, 12(12) 3657-60.

ots Originaltext: Ortho Biotech
Im Internet recherchierbar: http://www.presseportal.de

Contact:
Media Contact: William Foster, +1-908-541-4057, Investor Relations:
Tina Pinto, +1-732-524-2034
Quelle: http://www.worldofinvestment.com/news/intern//50240/
Avatar
15.04.08 14:50:03
Antwort auf Beitrag Nr.: 33.736.208 von spaceistheplace am 27.03.08 08:48:20Lieber space,

habe durch Zufall Deinen thread gefunden.

Langeweile macht sich auch hier - wie bei WMT - bezahlt:

Ich erwarte neue highs, Quartalsergebnis heute über dem Konsens, sogar über der höchsten Einzelschätzung.

Näheres kann jeder selber nachlesen.
Avatar
24.04.08 19:59:41
Johnson & Johnson erhöht Quartalsdividende um 10,8 Prozent
24.04.2008 - 16:46

NEW BRUNSWICK (dpa-AFX) - Der US-Pharma- und Medizintechnik-Konzern Johnson
& Johnson hat die Quartalsdividende um 10,8 Prozent erhöht. Nach zuvor 41,5 Cent je Aktie würden an die Anteilseigner nun 46 Cent ausgeschüttet, teilte das Unternehmen am Donnerstag auf seiner Hauptversammlung in New Brunswick mit.
Avatar
25.05.08 13:59:19
Auf der Suche nah Infos über die Firma bin ich auf das factsheet 2006 auf der J&J-homepage gestossen...


http://files.shareholder.com/downloads/JNJ/318267892x0x19112…


Interessant das der US-Anteil am Geschäft seit Jahren fast unverändert bei 56 % liegt und das der Pharmasektor 44 % beträgt - Pharmaabschlag + (jetzt) US-Abschlag erklären dann doch die nicht so dolle Kursentwicklung der letzten Jahre, obwohl sich das EPS in den letzten 10-12 Jahren gut ver3-facht hat. Natürlich sollte man auch nicht vergessen, das der Wert vor 10 Jahren stark überbewertet war und der US-Dollar seitdem auch kräftigst Federn lassen mußte.

Summasumarum wird mir J + J immer sympathischer; ein globaler Profiteur von Wachstum und Alterung unserer Gesellschaften der auch zusätzlich großes Wachstumspotential in Asien haben wird (momentaner Marktanteil < 5 %).
Avatar
25.05.08 14:03:13
Antwort auf Beitrag Nr.: 34.167.275 von IgnatzWrobel am 25.05.08 13:59:19Sorry, hab mich vertan...

....Anteil Asia/Pacific 13 % statt < 5 % --> trotzdem ausbaufähig! ;)
Avatar
15.07.08 21:51:15
Glückwunsch an alle Investierten:

Johnson & Johnson verbucht Ergebnisplus im zweiten Quartal


New Brunswick, NJ (aktiencheck.de AG) - Der amerikanische Konsumgüterkonzern Johnson & Johnson (ISIN US4781601046/ WKN 853260) legte am Dienstag die Geschäftszahlen für das zweite Quartal vor.
Demnach verbesserten sich die Umsatzerlöse im Vorjahresvergleich von 15,13 Mrd. Dollar auf 16,45 Mrd. Dollar, was einem Plus von 8,7 Prozent entspricht. Deutliche Zuwachsraten verzeichnete man vor allem in Europa (+16,4 Prozent) und in der Region Asien/Pazifik (+17,6 Prozent), während man in Nordamerika ein leichtes Umsatzplus von 2,1 Prozent zu verzeichnen hatte. Beim Nettogewinn wurden 3,33 Mrd. Dollar bzw. 1,17 Dollar je Aktie ausgewiesen, nach einem Nettogewinn von 3,08 Mrd. Dollar bzw. 1,05 Dollar je Anteilsschein im Vorjahreszeitraum. Ohne die Berücksichtigung von Einmaleffekten hatte der Gewinn je Aktie im Berichtszeitraum bei 1,18 Dollar gelegen. Analysten hatten zuvor ein EPS von 1,12 Dollar sowie einem Umsatz von 16,00 Mrd. Dollar erwartet.

Für das laufende Fiskaljahr erwartet der Konzern ein EPS von 4,45 bis 4,50 Dollar, wobei hier keine Einmaleffekte berücksichtigt sind. Insgesamt äußerte sich der Konzern trotz des derzeit schwierigen Umfelds optimistisch bezüglich der langfristigen Wachstumsaussichten. Analysten gehen für das laufende Geschäftsjahr von einem EPS von 4,45 Dollar sowie einem Umsatz von 64,26 Mrd. Dollar aus. Für das laufende Quartal erwarten Marktbeobachter ein EPS von 1,10 Dollar sowie einen Umsatz von 15,62 Mrd. Dollar.

Die Aktie von Johnson & Johnson notierte zuletzt bei 66,41 Dollar. (15.07.2008/ac/n/a)
Avatar
18.07.08 19:16:48
schöner Artikel / Überblick zu JNJ.

Gruss space

Try J&J's Plan for Healthy Growth

CHICAGO -- Growing your business is like planting a garden: You need to expand beyond a narrow patch of land; but scatter seeds too wide and you'll end up with an overgrown mess.

When it comes to smart growth, Johnson & Johnson (JNJ - Cramer's Take - Stockpickr) may be the model to follow. While health care companies as a whole have been beaten down in recent years, J&J recently reported quarterly earnings that beat Wall Street expectations.

Overall, second-quarter sales were $16 billion, an increase of 8% (3% if you factor out the effect of the weak dollar overseas). But the real growth was in consumer products, which were up 13%. "The reason Johnson & Johnson is performing so well in a very challenging environment is because of the diversity of their businesses," says Edward Jones health care analyst Linda Bannister. "They've made some smart acquisitions."
Best Way to Grow
Why so smart? J& J has managed to keep the company's basic health care DNA, while branching out into new but related fields. To grow your company successfully, you've got to navigate the same tricky path. The key is to expand without diluting your company's brand. Tack on too many unrelated products or services and no-one will know what you stand for.

"When Big Pharma was doing well a few years ago, there was a big push at some companies to get rid of other businesses," says Bannister. Indeed, Pfizer (PFE - Cramer's Take - Stockpickr) sold its consumer health care division to J&J in 2006, handing over brands such as Listerine and Visine. "At the time, a lot of people questioned the amount they paid, but in hindsight, it turned out well for them."

J&J is not immune to Big Pharma woes; sales of its prescription drugs grew 3%, but would have fallen 1% if not for favorable foreign exchange rates. The patent expired recently on its best-selling medication, the anti-psychotic Risperdal; next year, its Topomax epilepsy drug will also face competition from generics. And sales of Procrit, which treats anemia, fell after a report in the Journal of the American Medical Association said patients who took it had a 10% higher mortality rate.

But the company has been able to compensate for such losses through smart marketing of its consumer products. Bannister points to Neutrogena sunscreens as an example: "They do the research and development, putting scientific claims behind their products," she says. "That allows them to charge a premium, as well as target specific demographics."

Another key to J&J's success is knowing when to take a hands-off approach -- and when to collaborate. "They have a decentralized structure," she says. "Each unit is allowed to run independently. But they do a great job of sharing scientific breakthroughs."

Listerine's dissolving breath strips, for example, gave new life to the mouthwash category. J&J is now looking at ways they can use that same technology to deliver other medications.

The company's expertise in consumer marketing may also help their pharmaceutical division as more generics roll out. When their allergy medication Zyrtec went from prescription-only to over-the-counter, J&J was able to keep sales robust. "They understand how to launch a brand to consumers, and they benefit from having all those consumer business relationships," says Bannister. Not every health care company is as prepared when it comes to direct-to-consumer sales.

That focus on consumer relationships has helped maintain the company's positive image. "In general, the perception of Big Pharma among consumers is pretty low," says Bannister. "Johnson & Johnson is benefiting from putting their head down and executing."

By executing what you do best -- while expanding into related fields -- you too can enjoy Johnson & Johnson's most precious commodity: Consumer loyalty.
Avatar
19.07.08 10:55:43
Antwort auf Beitrag Nr.: 34.540.820 von spaceistheplace am 18.07.08 19:16:48wirklich guter Bericht, nicht nur immer die 0815 Soße der Analysten.

Ich glaub es wird Zeit dass ich einsteige...
Avatar
19.07.08 12:51:12
Antwort auf Beitrag Nr.: 34.543.105 von 1435905 am 19.07.08 10:55:43Jou, tu das!!! Ich bin eingestiegenvor 32 tagen, mein erster kauf nach der Pause...

Gruss space
Avatar
02.08.08 12:32:59
Johnson & Johnson buys out Dabao
By Yu Tianyu (China Daily)
Updated: 2008-08-01 15:13
Comments(0) PrintMail

Johnson & Johnson (China) Investment Co Ltd bought Beijing Dabao Cosmetics Co Ltd in a bid to further expand its presence in the Chinese market.

The subsidiary of the US -based consumer goods giant Johnson & Johnson acquired Dabao from Beijing Sanlu Factory and Beijing Dabao Co Ltd Staff Shareholding Committee. The deal is estimated at more than $300 million.

Johnson & Johnson won a bidding war with Avon and Unilever to acquire the company and will pay $337 million for Dabao.

"This transaction is an extension of our commitment to China, and to the continued development of China's consumer healthcare sector," said Jesse Wu, president of Johnson & Johnson (China) Investment Co Ltd.

"Dabao is a successful brand in the Chinese market. We are very pleased to add the well-known and respected Dabao brand to our growing portfolio of healthcare brands in China," he added.

However, there are concerns that international enterprises are invading China's household brands in the personal care industry. There are fears that China will lose more and more national brands in the future.

However, a source with Dabao said that the company's brand and brand-name products will remain.

Yang Zhigang from the Beauty and Cosmetics Chamber with the All-China Federation of Industry and Commerce told the Beijing News that the purchase of Dabao by Johnson & Johnson should not be regarded as a business failure, instead, it shows that China's household and personal care industry is gradually getting closer to reaching maturity and entering a capital era.

According to statistics, Dabao's sales reached 780 million yuan in 2005, accounting for 1 percent of the market share. Its sale declined to 676 million yuan in 2006.

"It is a wise decision for Dabao to get out of its current situation at a time when it still holds a renowned brand," Yang said.
Avatar
05.08.08 22:48:44
Heute hat JNJ das ATH geknackt! mal sehen, ob das jetzt den Kursdeckel wegfegt oder doch wieder ein rebound kommt wie schon 2 mal in den letzten jahren...es wird spannend...

Gruss space

Avatar
06.08.08 01:34:40
Antwort auf Beitrag Nr.: 34.655.887 von spaceistheplace am 05.08.08 22:48:44Hi space!

Reiner Zufall, aber ich hab heute auch bei J&J zugeschlagen. Hoffen wir mal das das ein gutes Omen ist! :cool:
Avatar
06.08.08 08:35:08
Antwort auf Beitrag Nr.: 34.656.469 von IgnatzWrobel am 06.08.08 01:34:40Hi space!

Reiner Zufall, aber ich hab heute auch bei J&J zugeschlagen. Hoffen wir mal das das ein gutes Omen ist!


Hi Ignatz, schön!!!! Willkommen im Bebe-, Penaten- und o.b. - Club...:laugh: Manche Produkte von JNJ sind ja für uns Männer nicht sooo geeignet...

Ich bin ja auch seit kurzem wieder dabei, wollte nicht erst warten, bis der Deckel weg fliegt. Sollte das aber nun eintereten können wir schnell mal ein paar Prozente nach oben gehen. Von der immer noch rel. niedrigen Bewertung ist das allemal zulässig.

Sollte es nicht klappen dürfte aber auch das Korrekturpotential sehr begrenzt sein. Vielleicht hält sich dann der Kurs ja gar an das Dreieck, das er seit rd. 3 Jahren ausgebildet hat. Dann sollte bei einer Korrektur um die 64 Dollar schluss sein.

Wie dem auch sei, Du bist in eines der besten Unternehmen de Welt investiert und wirst als Langfristinvestor Deine Freude am papier haben..

Gruss space
Avatar
11.08.08 21:13:01
Antwort auf Beitrag Nr.: 34.656.856 von spaceistheplace am 06.08.08 08:35:08 Willkommen im Bebe-, Penaten- und o.b. - Club... lachen Manche Produkte von JNJ sind ja für uns Männer nicht sooo geeignet...

Wieso? Das sind meine Standardkörperflegeprodukte! :D
Avatar
25.08.08 10:49:20
Antwort auf Beitrag Nr.: 34.703.607 von IgnatzWrobel am 11.08.08 21:13:01Hallo, bin wieder aus dem Urlaub zurück, hat gut getan und man sieht danach die Börse oft von einer anderen Seite bzw. dass man sich zu sehr damit beschäftigt....in den letzten 2 Woochen hat sich jedenfalls so gut wie nix getan im Endeffekt, ausser, dass der Dollar ein bisschen stärker geworden ist. Im Depotwert so gut wie keine Änderung bei mir.

Wieso? Das sind meine Standardkörperflegeprodukte!

Also gut!

Gruss space
Avatar
29.08.08 14:07:27
Judge Rejects J&J Patent On Alzheimer's Drug; Generic Looms8-28-08 9:32 AM EDT | E-mail Article | Print Article

DOW JONES NEWSWIRES

Barr Pharmaceuticals Inc. (BRL) said a federal court has invalidated a patent that clears the way for the generic-drug maker to sell its version of Johnson & Johnson (JNJ) Alzheimer's drug Razadyne.
Barr said the ruling effectively end the 30-month stay against the company's generic version. The judge also denied a temporary restraining order sought by J&J to stop Barr from launching its generic.

Razadyne, which had total sales of $214 million in the year ended June 30, is for mild to moderate dementia in Alzheimer's patients.

Barr says it will now begin marketing the drugs as soon as it receives final approval from the Food and Drug Administration. The company got tentative approval in May 2007.

J&J officials had no immediate comment.

Shares of Barr closed Wednesday at $67.58, up 15 cents, and there was no pre- market trading.

J&J's stock closed at $71.21, up 50 cents.

-By David Benoit, Dow Jones Newswires; 201-938-2472; david.benoit@ dowjones.com;

Click here to go to Dow Jones NewsPlus, a web front page of today's most important business and market news, analysis and commentary: http:// www.djnewsplus.com/al?rnd=CDxCAp3sEgCl%2B%2BFOYHhCsg%3D%3D. You can use this link on the day this article is published and the following day.
Avatar
11.09.08 14:28:52
JNJ ist ein Muster an Konstanz und aktueller outperformance!

Gehört in jedes langfristdepot!!!!

Gruss space

Hier noch ne Meldung

Sep 11, 2008 08:15 ET
J & J Produces Documents for Apaporis in Pre-Trial Investigation of Pharma Competitive Intelligence Conference Marketer Amy Yueh

TEANECK, NJ--(Marketwire - September 11, 2008) - Johnson & Johnson is the first of several major New Jersey and New York based pharmaceutical companies cooperating in the Amy Yueh investigation to provide internal files for the legal team prosecuting the case against her.

Ms. Yueh faces trial on January 26, 2009 in Hackensack, NJ, on charges of misappropriation of corporate property in a legal action that was initiated in December 2007 by Apaporis. Documents and witnesses are being sought from six drug companies with whom Ms. Yueh has had contact as part of the pre-trial preparation.

Files documenting Ms. Yueh's communications with several J & J employees from October 2005 through the present were delivered in compliance with a subpoena that was served to the company on July 7, 2008. Michele Bacorn, assistant to J & J counsel John O'Shaughnessy of J & J, stated, "We reserve the right to supplement the present response at a later date if we should locate additional relevant materials."

Sanofi-Aventis has also agreed to cooperate in the investigation especially targeting Ms. Yueh's activities from October through December of 2007. Senior Corporate Counsel Joshua Lubin, Esq. responded that the company will "produce responsive, non-privileged documents within its possession, custody, or control in response to the Subpoena."

Pfizer counsel Foster Gibbons has indicated by phone that his firm would cooperate. Further information is anticipated shortly.

Subpoenas requesting similar information seeking to document Ms. Yueh's activities with select drug companies have also been delivered to Merck, Novartis, and Bristol-Myers Squibb.

Apaporis specializes in content-driven conferences for the pharmaceutical and biotechnology industries. The limited liability corporation is privately held and located in Teaneck, NJ. Visit www.pharmabiotechci.com or www.chemoutsourcing.com for more information.
Avatar
12.09.08 13:17:57
Christine A. Poon Plans Retirement from Johnson & Johnson in Early 2009

NEW BRUNSWICK, N.J., Sept. 12 /PRNewswire-FirstCall/ -- Johnson&Johnson (News/Aktienkurs) said today that Christine A. Poon, 56, Vice Chairman of the Board of Directors and Worldwide Chairman, Pharmaceuticals Group, has announced plans to retire on March 1, 2009, from the Company and the Board, after more than 23 years in the health care industry and eight years with the Company.

William C. Weldon, Chairman and CEO, said, "Chris has been instrumental in helping to build Johnson&Johnson's pipeline of medicines to its place today as one of the world's most highly-regarded. We will certainly miss Chris' counsel, her leadership focus in building our pharmaceuticals business and her constant quest to bring better health and well-being to people around the world. She has exhibited strong leadership and personal involvement in building a skilled and diverse workforce. As a member of our Executive Committee and Vice Chairman, Chris has helped to shape Johnson&Johnson's strategy and vision for the future."

Ms. Poon began her career with Johnson&Johnson in November, 2000, as Company Group Chairman, Pharmaceuticals. In August, 2001, she was promoted to the Executive Committee and named Worldwide Chairman, Pharmaceuticals. Ms. Poon was appointed Worldwide Chairman, Medicines&Nutritionals, in October 2003. She was elected to the Johnson&Johnson Board of Directors and named a Vice Chairman of the Board in 2005. Prior to joining Johnson&Johnson, Ms. Poon spent 15 years at Bristol-Myers Squibb, where her most recent position was President of International Medicines. Ms. Poon is on the Board of Directors of Prudential Financial, Inc., in Newark, NJ, and the Fox Chase Cancer Center in Philadelphia, PA.

Mr. Weldon said a timely announcement of pharmaceutical succession plans will be made to ensure a smooth transition of Ms. Poon's Pharmaceuticals Group responsibilities.

About Johnson&Johnson

Caring for the world, one person at a time ... inspires and unites the people of Johnson&Johnson. We embrace research and science -- bringing innovative ideas, products and services to advance the health and well-being of people. Our 120,200 employees at more than 250 Johnson&Johnson companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.
Avatar
16.09.08 07:09:35
Boston Scientific Announces Court Decision

Last update: 5:47 p.m. EDT Sept. 15, 2008
NATICK, Mass., Sept 15, 2008 /PRNewswire-FirstCall via COMTEX/ -- Boston Scientific Corporation announced today a decision by the United States District Court in Delaware. The case involves a patent owned by Johnson & Johnson and Boston Scientific's NIR(R) stent product. In the decision, the Judge granted Johnson & Johnson's motion for entry of final judgment and denied Boston Scientific's motion for a new trial. In 2000, a jury awarded Johnson & Johnson $324 million in damages based on Boston Scientific's sale of the NIR stent. The Court also awarded pre-judgment interest at prime rate based on after-tax damages.
Today's Order indicated that the Court will enter final judgment on September 30, 2008.
Boston Scientific no longer sells the NIR stent. The Company announced that it will appeal this decision.
Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: http://www.bostonscientific.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding intellectual property litigation and competitive offerings. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.
Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A- Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file thereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.
Avatar
18.09.08 14:36:45
gute nachrichten:

UPDATE 1-J&J psoriasis drug beats top-seller Enbrel in trial

NEW YORK NEW YORK, Sept 18 (Reuters) - Johnson&Johnson (News/Aktienkurs) said on Thursday that its experimental psoriasis drug proved equally safe and more effective in a late-stage trial than top-selling treatment Enbrel, and required far fewer injections.

It was the first trial to pit J&J's ustekinumab against Enbrel, a blockbuster treatment for the chronic skin condition. Wyeth and Amgen sell Enbrel, which commands an estimated 75 percent share of the U.S. psoriasis market.

'I would anticipate, because of its robust clinical data and ease of administration, that once released, (ustekinumab) will certainly be a first-line drug' for psoriasis, said Dr. Alan Menter, a Baylor University dermatologist who helped lead the study.

Favorable results from the three-month trial of ustekinumab, which has been awaiting U.S. and European approval since late 2007, were seen among 903 patients with moderate to severe forms of the skin condition. Results were unveiled at a medical meeting in Paris.

J&J said in August that the FDA had extended its review of ustekinumab by three months, to December, to study recent amendments to the company's marketing application. But it said the agency did not request additional clinical trials.

Patients in the phase 3 study received either twice-weekly injections of Enbrel or either 45-milligram or 90-milligram injections of the J&J drug at the beginning of the trial and four weeks later.

After 12 weeks, 74 percent of those receiving the higher dose of ustekinumab and 68 percent on the lower dose achieved at least a 75 percent reduction in psoriasis symptoms, such as red scaly patches. That was deemed statistically superior to the 57 percent of those in the Enbrel group who obtained such relief. The J&J drug thereby comfortably met it primary study goal.

The new drug also met a secondary goal of proving superior to Enbrel in reducing the severity of psoriasis by 90 percent or more, considered nearly complete clearance.

Such relief was seen in 36 percent of patients on low-dose ustekinumab and 45 percent on the higher dose, versus 23 percent of those receiving Enbrel.

'We've never seen clearance along the lines of what we've been seeing with ustekinumab. This is pretty dramatic,' Menter told reporters in an interview before the data were formally presented.

Incidence of side effects was comparable in all three treatment groups, Menter said. But patients receiving ustekinumab had far fewer cases of redness or irritation at the injection site, largely explained by the fact that the J&J drug was given only twice during the study, compared with 24 injections of Enbrel.

(Reporting by Ransdell Pierson; Editing by Lisa Von Ahn and Steve Orlofsky) Keywords: JOHNSONANDJOHNSON/PSORIASIS

Chuck Mikolajczak
Avatar
18.09.08 23:16:08
By the way....


Schlußkurs in NY lag heute bei 70.93 USD (= 49.97 €). Schlußkurs in FRA heute 48.04 € (= -4.0 % zum US-Kurs). Ich dachte immer der Markt wäre - zumindestens bei den "Dickschiffen" - effizient? War wohl falsch gedacht.
Avatar
18.09.08 23:23:27
Antwort auf Beitrag Nr.: 35.177.670 von IgnatzWrobel am 18.09.08 23:16:08guck mal den tageschart an. Um 20 Uhr bzw. 2 UHr New Yorker Zeit war JNJ auf Tagestief bei rd. 69,25 Dollar. Macht in Euro bei 1.44 um diese zeit zeimlich genau 48,10 EUR. Spread noch berücksichtit, passt das 1:1, oder?

Gruss space

JNJ tageskurs:



Dollar:

Avatar
18.09.08 23:36:02
Antwort auf Beitrag Nr.: 35.177.748 von spaceistheplace am 18.09.08 23:23:27Dann bin ich ja beruhigt, danke :D


Auch die BRKA liegt im Vergleich zum US-Kurs - 3.9 % hinten...das sollte morgen einen sehr erfreulichen Handelsauftakt geben. :)
Avatar
20.09.08 15:26:03
J&J Could Slide In Market Rebound After Benefit From Turmoil9-19-08 2:59 PM EDT | E-mail Article | Print Article

Shares of health-care giant Johnson & Johnson (JNJ) have benefited in recent months as investors and mutual-fund managers sought safe harbors amid a storm on Wall Street, but they could slide the other way as confidence in the financial sector rebounds.
The company, with 2.8 billion shares outstanding and a nearly $200 billion market capitalization, is a fixture in many mutual funds, a component of the Dow Jones Industrial Average and an economically insulated place to hide when times get tough. But that effect cuts both ways, as evidenced by a slide in J&J shares on Friday as the broader market soared.

"You would think as people get more comfortable with the rest of the market, J&J would lose a little bit," said Matthew Dodds, a Citigroup analyst.

Still, he and other J&J observers don't expect a steep fall. Despite hitting a high this month, the company's valuation doesn't appear overinflated based on its historical record, and J&J's diverse portfolio of drugs, consumer products and medical devices remains an asset in an unsteady market.

Before Friday, the New Brunswick, N.J., company was tied with 3M Co. (MMM) and Walt Disney Co. (DIS) as the biggest percentage gainers this week among the Dow industrials, each up 0.5%, despite a very tumultuous period for the index.

On Friday, as the Dow Jones Industrial Average rocketed higher on hopes broad intervention by the U.S. government will provide a safe backstop for the fragile financial sector, J&J edged lower. Shares were recently down 93 cents, or 1.3%, to $70 after slipping as low as $69.21 earlier in the session.

"If in fact the market has marked a bottom, and the Fed and the central banks globally have managed to put a floor under these credit problems," then investors could redirect some holdings, said Peter Goldman, a principal at investment-counseling firm Front Barnett Associates LLC in Chicago, which holds J&J shares.

"It's not surprising that money would be flowing out of a J&J on a day like this," Goldman said. But "I wouldn't call it a threat," he added.

A J&J spokesman said the company doesn't comment on its stock price as a matter of policy.

A recent climb in J&J shares appeared coupled more to broader market factors than to fundamental issues within the company, which is battling some challenges in its pharmaceutical business, Dodds said. Shares are up about 9% since a lull in late June, and they crested at the new high of $72.76 on Sept. 9.

The drug business faces continuing generic competition and patent expirations for some big-selling drugs. Specifically, J&J's patent for the antipsychotic Risperdal expired this year, exposing it to generic competition, and patent protection for migraine drug Topamax is set to expire next year. Those drugs had more than $7 billion in combined sales in 2007.

J&J also faces heightened regulatory scrutiny of drug companies.

Elsewhere, the company's Cypher drug-coated heart stent is fading amid rising competition. Cypher has long been a big player in a multibillion-dollar stent market and a key J&J product.

Earnings Quality Questioned

The company has still put together a solid year, but "if you look at the quality of the earnings, it's not coming from the top line," or sales, which is where investors want to see growth over the long haul, Dodds said.

Instead, the company has leaned on items such as a cost-restructuring program and buybacks, he said. The restructuring program aims for annual, pre-tax cost savings of $1.3 billion to $1.6 billion this year - J&J has said it's likely to hit the high end of that range. Meanwhile, as of June 29, the company had repurchased about $6.4 billion worth of shares as part of a $10 billion buyback program it launched last summer.

"So really in this period, the stock's been going up as their earnings have been coming from lower-quality areas," Dodds said. That indicates "the defensive nature of J&J" has made it attractive as nervous investors backed away from financial stocks, he said.

Still, Dodds has a buy rating on J&J shares, and he isn't concerned about J&J sliding too far if the market shifts course. The company's current valuation of 15.7 times expected current-year earnings is far ahead of some major pharmaceutical peers that are hovering in the high-single digit range, but is also about 12% below J&J's five-year average.

J&J has huge medical-device and consumer businesses, along with its drug business, which can offer insulation that other drug makers don't have. This mix paid dividends in the second quarter, when strong consumer-product and medical- devices sales helped offset weakness in drugs to drive an 8% earnings gain. J&J boosted its full-year earnings forecast after that earnings report.

"I look at [J&J] literally like a mutual fund," investor Goldman said. "If one area is having a problem, it doesn't derail the whole thing."

Other conglomerates offer a similar benefit, but health care in particular is seen as a defensive sector when the economy sours. "You can't hide in GE - it's half a financial," Goldman said, referring to General Electric Co. (GE).

J&J posted sales of $61.1 billion last year, with about 41% coming from drugs, 35% from medical devices and 24% from consumer products.

Marc Davis, portfolio manager at Tradition Capital Management and a J&J shareholder, said he believes J&J shares have a good long-term outlook because of this diverse model. Also, he said J&J has several drugs in its late-state research pipeline that could help reignite growth in coming years.

"I would sort of ignore the noise day to day," Davis said.

Citigroup has had an investment-banking relationship with J&J, and has acted as a manager or co-manager for J&J securities in the last year.

-By Jon Kamp, Dow Jones Newswires; 617-654-6728; jon.kamp@dowjones.com

(Peter Loftus contributed to this report.)

Click here to go to Dow Jones NewsPlus, a web front page of today's most important business and market news, analysis and commentary: http:// www.djnewsplus.com/al?rnd=Tuf6jlTSR9asUD3iYofXbg%3D%3D. You can use this link on the day this article is published and the following day.

(END) Dow Jones Newswires
09-19-081459ET
Copyright (c) 2008 Dow Jones & Company, Inc.
Avatar
07.10.08 19:20:48
Johnson & Johnson to Host Analyst Meeting to Discuss Third-Quarter Financial Results and Review Pharmaceutical Business

Last update: 11:20 a.m. EDT Oct. 7, 2008
NEW BRUNSWICK, N.J., Oct 07, 2008 /PRNewswire-FirstCall via COMTEX/ -- Johnson & Johnson will host an analyst meeting at 8:30 a.m. (Eastern Time) on Tuesday, October 14, 2008, to discuss third-quarter financial results and review its Pharmaceutical business. The meeting will be hosted by Christine Poon, Vice Chairman, Board of Directors and Worldwide Chairman, Pharmaceuticals Group; Paul Stoffels, Company Group Chairman, Global Research and Development, Pharmaceuticals Group; Dominic Caruso, Vice President, Finance and Chief Financial Officer; and Louise Mehrotra, Vice President, Investor Relations.
Avatar
14.10.08 19:45:57
JNJ ist mustergültig. Die aktuellen zahlen garn über den Erwartungen. Prognose angehoben. was will man mehr.
Wie so oft gesagt: Absolute Pflichtaktie in jedem langfristdepot!!!

Gruss space

Johnson & Johnson erhöht Jahresgewinnziel nach starken Quartalszahlen
14.10 14:18

NEW BRUNSWICK (AWP International) - Der amerikanische Pharma- und Medizintechnik-Konzern Johnson & Johnson (J&J) hat im dritten Quartal die Erwartungen übertroffen und das Jahresgewinnziel aufgestockt. Statt eines Gewinns von 4,45 bis 4,50 Dollar je Aktie stellte J&J am Dienstag in New Brunswick 4,50 bis 4,53 Dollar in Aussicht. Im dritten Quartal erhöhte sich der Überschuss von 1,06 auf 1,17 Cent je Aktie. Analysten hatten im Schnitt mit 1,12 Dollar gerechnet.

Auch beim Umsatz übertraf das Unternehmen die Prognosen. Mit einem Anstieg von 14,97 auf 15,9 Milliarden liess J&J die Durchschnittsschätzung von 15,7 Milliarden Dollar hinter sich. Im vorbörslichen New Yorker Handel zog die Aktie um 3,7 Prozent an.
Avatar
14.10.08 19:52:09
Johnson & Johnson ist topfit
Für Johnson & Johnson ist Krise zurzeit noch ein Fremdwort. Der US-Pharma- und Medizintechnikkonzern steigerte im dritten Quartal Umsatz und Gewinn stärker als erwartet und hob erneut die Jahresprognose an.
Bild zum Artikel Penate-Creme von Johnson & Johnson

Für das laufende Jahr peilt Johnson & Johnson nun einen Gewinn je Aktie von 4,50 bis 4,53 Dollar an. Bisher hatte die Prognose bei 4,45 bis 4,50 Dollar gelegen.

Analystenerwartungen übertroffen
Das Geschäft des Herstellers von Gesundheitsprodukten läuft glänzend. Im dritten Quartal übertraf Johnson & Johnson die Erwartungen. Der Gewinn je Aktie erhöhte sich von 1,06 Dollar auf 1,17 Dollar je Aktie. Analysten hatten lediglich 1,11 Dollar auf ihrer Rechnung.

Der Umsatz stieg um mehr als sechs Prozent auf 15,9 Milliarden Dollar. Auch hier wurden die Analysten-Prognosen von 15,7 Milliarden leicht geschlagen.

Wachstum vor allem außerhalb der USA
Günstige Wechselkurseffekte und deutliche Zuwächse auf den internationalen Märkten außerhalb der USA beflügelten das Wachstum. Laut Vorstandschef William Weldon trugen maßgeblich die Verbrauchersparte und das Geschäft mit medizinischen Geräten und Diagnostikprodukten zum guten Ergebnis bei. Das Verbrauchergeschäft wuchs zweistellig um 13 Prozent, Medizintechnik und Diagnostikprodukte verzeichneten ein Plus von fast neun Prozent. Sorgenkind war lediglich die Pharmasparte, die auf ihrem Niveau stagnierte. Ohne Wechselkurseffekte hätte es gar einen Umsatzrückgang geben.

Johnson & Johnson ist für seine Pflegeprodukte bekannt, darunter sind zum Beispiel Marken wie Penaten, bebe, o.b. und Neutrogena. Daneben gehören Produkte aus dem Bereich Gesundheit zur Angebotspalette, also zum Beispiel Medikamente. J&J ist der Entwicklungspartner von Bayer bei dessen neuem Thrombosehemmer Rivaroxaban. Daneben stellt J&J medizinische Geräte her.

Die Aktien von Johnson & Johnson stiegen an der US-Börse um rund fünf Prozent auf 66 Dollar. Damit notieren sie exakt auf dem Niveau von Anfang des Jahre
Avatar
17.10.08 14:07:26
J&J recalls narcotic pain system sold in Europe

A Johnson & Johnson company is recalling an advanced pain patch system for post-surgery hospital patients after some units of the needleless system were found to possibly be able to activate themselves, posing a potential risk of narcotic overdose.

By LINDA A. JOHNSON

AP Business Writer
TRENTON, N.J. —

A Johnson & Johnson company is recalling an advanced pain patch system for post-surgery hospital patients after some units of the needleless system were found to possibly be able to activate themselves, posing a potential risk of narcotic overdose.

The Ionsys transdermal system has been recalled from the 11 countries in Europe where it has been on the market since being launched in January, Greg Panico, a spokesman for J&J's Ortho McNeil unit, said Thursday. The defect was found among products being prepared for shipment at a distribution center, he said, and there have been no reports of patients being harmed.

The product has never been on the market in the U.S., although it was approved at one point.

Ionsys was designed as an advance over current systems that let hospitalized patients with significant pain press a button to get an intravenous dose of a powerful painkiller. Instead, it uses a low-intensity electrical field, barely noticeable to the patient, that rapidly moves the drug inside into the patient's skin and then bloodstream, according to Panico.

The three-part device, slightly smaller than a credit card, has a top layer with electronics, a tiny battery and a button to activate it; a middle layer containing the narcotic pain reliever fentanyl, and an adhesive patch that adheres to the patient's chest or upper arm. The design allows patients to avoid an IV and move around a bit more, and it eliminates the danger of needlestick injuries.

Ionsys was approved in this country in May 2006, but Johnson & Johnson decided to make an improvement in the manufacturing method and submitted a new application to the Food and Drug Administration this spring, Panico said. That was rejected in August, and the company is still addressing FDA's questions and trying to decide its next step.

"It's a faster, better, cheaper way of administering fentanyl," said analyst Steve Brozak of WBB Securities.

But he said the fact that it contains such a powerful narcotic may have made reviewers skittish at the FDA, which has become increasingly cautious about approving new drugs and devices.

"It sends a chilling message that if you want to improve a medical device, you run the risk of losing the product" approval, Brozak said, assuming that J&J is correct about the change only involving manufacturing technique.

He thinks the company can find a way to get the product on the market here if it is willing to invest enough money and energy. But Brozak said the product likely would bring only $100 million to $200 million in annual sales because it is limited to use in hospitals.

Meanwhile, Panico said, the company is trying to determine whether it was a problem with the electronics or something else that caused the device failure that led to the European recall.

"Once we have the root cause of that, we'll look at our options and make a decision" as to what to do next, Panico said.

He said 13,000 of the devices have been distributed to date in Europe, of which 6,700 have been returned since the recall, announced on Sept. 25. The remaining 6,300 were used to treat patients.
Avatar
24.10.08 07:28:57
Hier ne Studie mit ein paar Infos:

Johnson & Johnson halten (Raiffeisen Centrobank AG)


Wien (aktiencheck.de AG) - Connie Schümann und Christine Nowak, Analystinnen der Raiffeisen Centrobank, stufen die Aktie von Johnson & Johnson (ISIN US4781601046/ WKN 853260) weiterhin mit "halten" ein.
Johnson & Johnson sei der weltweit größte Hersteller von Drogerie- und Gesundheitsprodukten. Das Unternehmen gliedere sich in drei Geschäftsbereiche: medizinische Geräte, Pharma (Procrit: Medikament für Blutarmut; Topamax: Epilepsiemedikament, diverse Krebsmedikamente) und Konsumgüter-/Hygieneprodukte (Marke bebe, Zahnbürsten, Fußpflege). Reges Interesse zeige der Konzern immer wieder an der Übernahme kleinerer Biotechfirmen sowie Medizintechnik-Unternehmen.

Es lese sich beinahe wie ein Déjà-vu, wieder gelinge dem Unternehmen ein guter Start in die Berichtssaison, wieder treibe das Konsumgeschäft das Ergebnis und wieder werde der Ausblick leicht angehoben. Doch der Teufel liege im Detail, denn das gute Ergebnis beruhe auch auf einigen Sondereffekten.

Negativ falle auf, dass die Bruttomarge etwas niedriger als erwartet ausgefallen sei und Forschungsausgaben gekürzt worden seien. Ebenfalls nicht nachhaltig sei die niedrige Steuerquote.

Für das Medikament Xarelto (gegen Thrombose), das von Bayer entwickelt worden sei und von Johnson & Johnson in den USA vertrieben werde, gebe es erste Indikationen für den Preis (dieser sei höher als erwartet). Das Medikament habe aber auch klare Vorteile (sehr gute Effizienz und orale Verfügbarkeit). Der Ausblick für den Gewinn pro Aktie für das laufende Geschäftsjahr sei leicht erhöht worden.

Johnson & Johnson sei ein sehr defensives, gut diversifiziertes Pharmaunternehmen. Das Risiko scheine im Vergleich zu anderen Pharma-Unternehmen auch begrenzt. Im Gesundheitssektor stelle es sicher eines der attraktivsten Investments dar. Aufgrund der Größe werde es aber schwer weiter stark zu wachsen. Zudem würden die Auslöser für eine Neubewertung der Aktie fehlen.

Die Produktivität der klinischen Forschung sei im Sektorvergleich ebenfalls nicht schlecht, aber es werde noch etliche Jahre dauern, bis das jeweilige Effizienz-Nebeneffekte-Profil bestätigt werde. Dann müsse die FDA das Medikament noch zulassen. Das heiße, die Aktie möge in diesem volkswirtschaftlichen Umfeld zwar weiter gut abschneiden, aber ein absoluter Kursanstieg scheine von diesem Niveau aus schwer vorstellbar.

In Summe bleiben die Analysten der Raiffeisen Centrobank daher bei ihrer "halten"-Einschätzung für die Johnson & Johnson-Aktie. (Analyse vom 22.10.2008) (22.10.2008/ac/a/a)
Analyse-Datum: 22.10.2008

Analyst: Raiffeisen Centrobank AG
KGV: 14.1
Rating des Analysten: halten


Quelle: aktiencheck.de 23.10.2008 15:21:00
Avatar
27.10.08 11:22:13
wer sie noch nicht hat, KAUFBEFEHL!

Sogar die Wirtscahftswoche blicht es...

Johnson & Johnson chancenreich (Wirtschaftswoche)


Düsseldorf (aktiencheck.de AG) - Nach Ansicht der Experten der "Wirtschaftswoche" ist die Aktie von Johnson & Johnson (ISIN US4781601046/ WKN 853260) chancenreich.
Da Unternehmen habe die Ertragsprognose erhöht, nach einem überraschend starken Gewinnanstieg von 7,6% auf 1,17 USD je Aktie im 3. Quartal. Nun sollten für 2008 mindestens 4,50 USD je Aktie erwirtschaftet werden. Der Umsatz sei innerhalb der ersten neun Monate auf 48,6 Mrd. USD gestiegen. Somit deute alles daraufhin, dass es am Jahresende etwa 65 Mrd. USD sein würden, was einer 6-prozentigen Verbesserung gegenüber dem Vorjahr entspreche..

Derartige Aussichten seien nicht nur Balsam für krisengeschüttelte Anleger. Sie würden auch verdeutlichen, dass Johnson & Johnson gelernt habe mit dem größten Problem der Pharmabranche, der Konkurrenz der Generikaproduzenten, umzugehen.

Zudem sei das Unternehmen mit 48 Mrd. USD Eigenkapital, bei langfristigen Schulden in Höhe von 7 Mrd. USD solide finanziert.

Die Experten der "Wirtschaftswoche" halten die Johnson & Johnson-Aktie für chancenreich. Ein Stoppkurs werde bei 49,70 USD empfohlen. (Ausgabe 44)
(27.10.2008/ac/a/a)
Analyse-Datum: 27.10.2008

Analyst: Wirtschaftswoche
KGV: 14.1
Rating des Analysten:
Avatar
28.10.08 07:43:20
JNJ kauft Wellness Firma:

Johnson & Johnson Establishes Wellness & Prevention Platform with Acquisition of HealthMedia, Inc.

NEW BRUNSWICK, N.J., Oct 27, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- As an initial step in the creation of a wellness and prevention business platform, Johnson & Johnson announced today it has acquired HealthMedia, Inc., a privately held company located in Ann Arbor, Michigan, that creates web-based behavior change interventions. Terms of the transaction were not disclosed.

HealthMedia combines advanced technology and behavioral science to effectively emulate a health coach via the web. HealthMedia's suite of interventions provides automated web-based coaching for wellness, disease management, behavioral health, and medication adherence with proven outcomes, increased compliance, reduced medical utilization, and increased productivity. HealthMedia's products have demonstrated improved cost savings for health plans and employers.

William C. Weldon, Johnson & Johnson Chairman and Chief Executive Officer, said: "It is exciting for Johnson & Johnson to establish a new business platform to offer customers meaningful products and services focused on wellness and prevention that reduce healthcare costs, and at the same time, deliver new growth for our Company. Global healthcare systems, including governments, employers, payers and individuals, are seeking new solutions to more effectively manage spiralling costs of care. Our establishment of a Wellness & Prevention platform recognizes our conviction that a comprehensive solution must begin long before the onset of illness, and that investing in wellness and prevention now can avoid more costly health care expenses later.

"This acquisition represents a critical first step in Johnson & Johnson's commitment to providing products and services that enable consumers to adopt lifestyles and behaviors that reduce the risk of preventable chronic diseases and sustain good health," Mr. Weldon continued.

Nicholas J. Valeriani, Vice President, Johnson & Johnson Office of Strategy & Growth, who is responsible for the Wellness & Prevention platform, said: "Johnson & Johnson has incorporated HealthMedia programs into our health and wellness initiatives for a number of years, generating documented improvements that we are confident other employers and healthcare providers will find beneficial. In the U.S., where the programs have been implemented, they have contributed to our employees' ability to lose weight and increase physical activity, reduce stress, quit smoking, manage diabetes, and improve medication compliance."

"At Johnson & Johnson, a focus on health and wellness, including HealthMedia's programs, has helped to reduce our per capita health-plan costs and improve overall employee health and productivity. We are confident that a combination of proven products and services will enable our customers to better manage chronic disease, improve overall health, and create more productive workforces. The acquisition of HealthMedia is an important first step in this effort."

HealthMedia, Inc. was founded in 1998 and has approximately 140 employees. For more information, visit www.healthmedia.com.

About Johnson & Johnson

Caring for the world, one person at a time... inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Our 119,400 employees at more than 250 Johnson & Johnson companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.

SOURCE Johnson & Johnson

http://www.healthmedia.com
Avatar
30.10.08 10:19:43
deswegen die überproportionalen Abschläse gestern.

Johnson & Johnson Downgrade (JPMorgan Chase & Co.)


New York (aktiencheck.de AG) - Michael Weinstein, Analyst von J.P. Morgan Securities, stuft die Aktie von Johnson & Johnson (ISIN US4781601046/ WKN 853260) von "overweight" auf "neutral" zurück.
In Zeiten der wirtschaftlichen Krise werde Johnson & Johnson weithin als sicherer Hafen angesehen. Auf Grund der vergleichsweise geringeren Kurseinbußen notiere die Aktie mittlerweile schon mit einem Aufschlag von 64% gegenüber reinen Pharmaunternehmen. In den letzten 20 Jahren habe die Prämie nie mehr als 35% betragen.

Johnson & Johnson sei zwar defensiv aufgestellt, habe ein AAA-Rating und repräsentiere praktisch einen Healthcare-Investmentfonds. 2009 werde aber eines der härtesten Jahre in der Unternehmensgeschichte. Zwei der drei größten und auch gleichzeitig profitabelsten Medikamente würden von generischer Konkurrenz bedroht. Das Gewinnwachstum stehe damit vor erheblichen Herausforderungen. Über 2009 hinaus dürfte sich die Lage auf Grund der starken Pipeline wieder etwas entspannen.

Vor diesem Hintergrund lautet die Einschätzung der Analysten von J.P. Morgan Securities für die Aktie von Johnson & Johnson nunmehr "neutral". (Analyse vom 29.10.08) (29.10.2008/ac/a/a) Analyse-Datum: 29.10.2008

Analyst: JPMorgan Chase & Co.
Rating des Analysten: neutral
Avatar
08.11.08 15:28:00
Antwort auf Beitrag Nr.: 35.760.050 von spaceistheplace am 30.10.08 10:19:43Hallo Space,
wo siehst du das Kursziel von J&J?
Avatar
10.11.08 16:35:09
Antwort auf Beitrag Nr.: 35.883.884 von AlexU am 08.11.08 15:28:00Hallo Space,
wo siehst du das Kursziel von J&J?


So was habe ich nicht. Ich halte das teil bis zu meiner Rente, oder ves wird vererbt...
Wird dann genau so hoch im Kurs liegen wie jetzt, nur haben wir dazwischen ein paar Splits gesehen...:D

Ein Verkauf kommt evtl. dann in Betracht, wenn wir soo eine Bewertungsblase haben wie in 2000, sagen wir ein KGV von 40-50. So hoch war es mal in 1986, 1992, 1999. Da lag ne Überteuerung vor, der Kurs ging dann längers seitwärts, nippelte aber auch nicht ab. Die Divis sind ja auch nett...

Gruss space
Avatar
11.11.08 14:00:58
Hi,

ich habe heute einen Brief von meiner Depotbank gekriegt.
Betreff: Kapitalmaßnahme J&J.

K&N (WKN 907665) bietet für jede Aktie von J&J eine eigene Aktie.

Weiß jemand was darüber?:rolleyes:
Avatar
11.11.08 14:07:59
Antwort auf Beitrag Nr.: 35.911.010 von AlexU am 11.11.08 14:00:58Weiß jemand was darüber?

neee, sorry. ich habe keine Mitteilung.

Gruss space
Avatar
11.11.08 18:37:42
J&J Device Tops Drugs In Treating Heart-Rhythm Issue - Study11-11-08 11:51 AM EST | E-mail Article | Print Article

New study data released Tuesday indicate treatment with a catheter-based system made by a Johnson & Johnson (JNJ) unit can help patients avoid recurrence of a common heart-rhythm disorder called atrial fibrillation better than the use of drugs.
This is the first U.S. Food and Drug Administration-vetted clinical trial to show this result, according to J&J's Biosense Webster, which is trying to leverage the data to win FDA approval to market its system for atrial fibrillation. The rhythm problem has already generated a fast-growing market for catheter-based treatment in the U.S., although no company has FDA approval to actually market such devices for this purpose.

Biosense Webster would like to cross that line and be first in a field where competitors include St. Jude Medical Inc. (STJ), Medtronic Inc. (MDT) and Boston Scientific Corp. (BSX), and where unapproved device usage has drawn some scrutiny. Boston Scientific and another company, AtriCure Inc. (ATRC), have each recently disclosed letters indicating a U.S. Justice Department investigation into use of surgery-based systems to treat atrial fibrillation.

An FDA panel of experts will meet on Nov. 20 to review using Biosense Webster's "NaviStar ThermoCool" catheter to specifically treat the rhythm problem.

"The reason we think it's so important [to get approval] is we think it's critical that we be able to participate in the training" for atrial-fibrillation treatment, said Marcia Yaross, vice president of clinical, regulatory and health policy at Biosense Webster. Treatment procedures are complex and there is a steep learning curve.

Atrial fibrillation is a common type of irregular heart rhythm in the U.S., where it affects more than two million people. The problem, which involves very fast and disorderly beating in the heart's upper chambers, can boost the risk of strokes and other complications.

Patients with atrial fibrillation are most often treated with drugs, which frequently don't help. There is a growing market for back-up treatment with medical devices that carefully destroy, or ablate, heart tissue linked to the problem. There are different systems that ablate tissue with energy that are used during regular surgery, or during less invasive procedures where catheters are threaded to the heart through blood vessels.

Catheter-based techniques have been taking over as a preferred option, backed by improving technology that helps doctors find the problem area, said Mark Estes, who is president of the Heart Rhythm Society. The group represents electrophysiologists such as Estes who treat heart-rhythm issues. He practices at Tufts Medical Center in Boston.

The odds of curing atrial fibrillation with one catheter-based procedure are now about 75% to 80%, Estes said.

Avoiding Recurring Problems

Data from the Biosense Webster-backed study were released Tuesday at the American Heart Association's annual scientific conference. A total of 167 patients who had failed treatment with at least one drug were enrolled and tracked for nine months to see whether treatment with different drugs or ablation was more likely to stop symptomatic atrial fibrillation from recurring.

The reduction in recurrence among patients treated with the Biosense Webster system was significantly higher, at 75%, than the 21% reduction seen among patients treated with drugs. There were also fewer serious adverse events at 90 days - a pre-specified follow-up point in the study - among patients treated with the device.

Device-based atrial-fibrillation treatment already represents an approximate $ 1.5 billion global market and a rapidly expanding U.S. market, according to Stanford Group analyst Jan Wald. The annual sales growth profile tops 20%, he said.

Certain devices are approved for atrial-fibrillation treatment overseas, but not in the U.S. The domestic market has still taken off, however, because devices are already available based on FDA clearance for other issues.

This usage has made atrial-fibrillation treatment tricky to study, because patients who have failed one drug may not want to try another - as a study may require - when they have clear access to device treatment.

In the Biosense Webster study, nearly 5,300 patients were screened to get to 167 participants, partially due to this issue. The study looked for patients who had already tried drug treatment because major heart associations have said catheter-based treatment should be reserved for such cases.

Despite such challenges, there are studies underway across the sector aimed at bolstering evidence for device-based treatment, including a St. Jude-supported study examining catheter ablation and an AtriCure study examining its surgical system.

Boston Scientific and Medtronic have long had ablation devices, but recently moved to buy companies that make systems that freeze tissue to treat rhythm issues and also have studies underway aimed at U.S. approval for atrial fibrillation.

Medtronic should soon close on the purchase of CryoCath Technologies Inc., which, if its study goes well, could win FDA approval in 18 months or so to treat atrial fibrillation with its system. Medtronic is also forming a specific atrial-fibrillation business unit within its big heart-rhythm-disease management business.

The push toward FDA approval comes amid some disclosures regarding the Justice Department scrutiny of surgical ablation. AtriCure shares sank last week after it disclosed a letter from the agency, received Oct. 27, regarding an investigation into the company's marketing practices for its system and atrial fibrillation.

Boston Scientific, meantime, disclosed in a Securities and Exchange Commission filing that it received a Justice Department letter on Oct. 24 "informing us of an investigation relating to surgical cardiac ablation system devices to treat atrial fibrillation."

A Justice Department spokesperson couldn't be reached for comment Tuesday regarding the scope of this investigation.

-By Jon Kamp, Dow Jones Newswires; 617-654-6728; jon.kamp@dowjones.com

Click here to go to Dow Jones NewsPlus, a web front page of today's most important business and market news, analysis and commentary: http:// www.djnewsplus.com/al?rnd=6NlmY0aFxCN%2F%2BlgX8%2BRclQ%3D%3D. You can use this link on the day this article is published and the following day.
Avatar
14.11.08 06:15:58
Nachdem ich mich bereits vor einiger Zeit entschlossen habe einen Teil meines Börsenkapitals in diese Aktie zu investieren, begrüße ich alle Investierten und stelle auch eine neue Meldung hier ein.

gruss
shaba :D



New Antibiotic Against Serious Infections - Receives First Approval in Europe
ZEVTERA™ A Broad-spectrum, Anti-MRSA Cephalosporin Antibiotic to Treat Complicated Skin and Soft Tissue Infections Approved in Switzerland

Baar, Switzerland (November 13, 2008) - Swissmedic, the Swiss agency for therapeutic products, has approved ZEVTERA™ (ceftobiprole medocaril) for the treatment of complicated skin and soft tissue infections, including diabetic foot infections which have not spread to the bone.

Ceftobiprole is licensed from and co-developed with Basilea Pharmaceutica Ltd. Janssen-Cilag will market ceftobiprole in Switzerland under the trade name ZEVTERA™. Swiss based Basilea Pharmaceutica Ltd will co-promote the drug in key European markets and North America.

Ceftobiprole is the first, broad-spectrum, anti-MRSA cephalosporin antibiotic with activity against a range of difficult-to-treat Gram-positive and Gram-negative hospital- and community-acquired pathogens including methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa1. In clinical trials, ceftobiprole has demonstrated high cure rates in patients with complicated skin infections, including those caused by the potentially deadly MRSA.

Data from the European Antimicrobial Resistance Surveillance System (EARSS) show that the prevalence of MRSA - a difficult to treat cause of hospital-and- community acquired infections - while varying considerably among countries, has been rising across Europe for the past six years2.

The use of ceftobiprole in adults for the treatment of complicated soft tissue infections, including diabetic foot infections which have not spread to the bone, is under regulatory review in United States, Australia and in the European Union among other countries. In Canada, ceftobiprole was launched in August 2008 under the trade name ZEFTERA.

About Complicated Skin Infections

Complicated skin and soft tissue infections are among the most common infections in the hospital setting. Staphylococcus aureus is the predominant pathogen in these infections. In recent years, resistant strains, such as MRSA have become increasingly common and have been associated with increased morbidity and mortality. New broad-spectrum antibiotics that cover resistant bacteria such as MRSA, but also clinically important and problematic Gram-negative pathogens, address a high-unmet medical need in the treatment of severe skin and soft tissue infections.

Patients with chronic wounds or those who have recently received antibiotics may also be infected by Gram-negative pathogens. This is frequently the case for diabetic patients with foot infections. Adequate treatment of diabetic foot infections can require hospitalization, surgery and broad-spectrum intravenous antibiotics.

About Ceftobiprole

Ceftobiprole, the first anti-MRSA cephalosporin to be approved, is an intravenous antibiotic that belongs to the class of antibacterial drugs known as cephalosporins, which are used to treat serious infections caused by a broad range of bacteria, characterized as Gram-negative and Gram-positive, based on a classification process that is used to identify the specific type of bacteria.

Phase III clinical trials have demonstrated that ceftobiprole is clinically efficacious against the following pathogens: Enterobacter cloacae, Enterococcus faecalis, Proteus mirabilis, Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus agalactiae, Streptococcus pyogenes, Escherichia coli, Klebsiella pneumonia and Pseudomonas aeruginosa.

The Janssen-Cilag company have a long and successful track record in developing and marketing treatments for a wide variety of conditions such as infectious disease, HIV, pain management, fungal infections, multiple myeloma, gastroenterological disorders, epilepsy, Alzheimer's disease, schizophrenia, acute bipolar mania, behavioural psychological symptoms of dementia, disruptive behaviour disorders, and autism. More information can be found at http://www.janssen-cilag.com. The Janssen-Cilag companies are part of the Johnson & Johnson family of companies.

This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Janssen-Cilag's expectations and projections. Risks and uncertainties include general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 30, 2007. Copies of this Form 10-K, as well as subsequent filings, are available online at http://www.sec.gov, http://www.jnj.com or on request from Johnson & Johnson. Janssen-Cilag does not undertake to update any forward-looking statements as a result of new information or future events or developments.

1 Pseudomonas aeruginosa, a gram-negative pathogen, causes a variety of infectious diseases and is the most significant cause of hospital acquired infections particularly in pre-disposed patients with metabolic, haematologic, and malignant diseases.

2 European Antimicrobial Resistance Surveillance System (EARSS) 2005 Annual Report. Available at: http://www.rivm.nl/en/
Avatar
14.11.08 14:30:57
Antwort auf Beitrag Nr.: 35.943.943 von shaba am 14.11.08 06:15:58
Nachdem ich mich bereits vor einiger Zeit entschlossen habe einen Teil meines Börsenkapitals in diese Aktie zu investieren, begrüße ich alle Investierten und stelle auch eine neue Meldung hier ein.

willkommen im JNJ-Club, shaba!
Wirst es nicht bereuen! JNJ ist eines der besten Unternehmen überhaupt. ich kann es nur noch mal wiederholen: seit 47 Jahren steigende Gewinne jährlich, steigende Divis. Zudem kaum Schulden hoher cash flow...
Super Management und die produkte erhaben

Gruss space
Avatar
14.11.08 14:49:45
Antwort auf Beitrag Nr.: 35.947.473 von spaceistheplace am 14.11.08 14:30:57dankeschön spaceistheplace,

ja ich habe auch den eindruck dass ich in zeiten wie diesen hier sehr gut aufgehoben bin.
die website und die fast täglich eingehenden meldungen über diesen giganten der pharmabranche, sind sehr überzeugend-ebenso das täglich gehandelte volumen.

ich gehe davon aus dass du bereits längere zeit bei JNJ investiert bist und dadurch auch am letzten stand. wie siehst du das target innerhalb der nächsten 12 monate? ist 70$ realistisch?

ich werde gerne mitarbeiten und mir alles zugängliche und auch interessante hier einstellen.

gruß,
shaba :D
Avatar
14.11.08 14:55:54
Antwort auf Beitrag Nr.: 35.947.653 von shaba am 14.11.08 14:49:45giganten der pharmabranche

Pharma macht rd. 1/3 aus, Medtech noch mal so viel und consumer staples (bebe, fenjal, tampons etc.) noch mal ein Drittel, also breit aufgestellt. gerade die Pharmabranche wächst aktuell nicht.


ich gehe davon aus dass du bereits längere zeit bei JNJ investiert bist und dadurch auch am letzten stand.

jou, mit Unterbrechungen seit 1995


wie siehst du das target innerhalb der nächsten 12 monate? ist 70$ realistisch?

habe ich nicht, bin Langfristinvestor und da habe ich keine Kursziele. Langfristig zählen nur die Aktiensplits...:laugh::laugh::laugh:

ich werde gerne mitarbeiten und mir alles zugängliche und auch interessante hier einstellen.

jou, nur zu! Dann muss ich es hier nicht alleine machen wie bisher. :D

Gruss und schönes Wochenende
space
Avatar
14.11.08 15:05:14
Antwort auf Beitrag Nr.: 35.947.703 von spaceistheplace am 14.11.08 14:55:54(bebe, fenjal, tampons etc.)

und die windeln werden auch regelmässig "gefüllt" :laugh::laugh:

das mit den aktiensplits ist natürlich um vieles besser, werde mich darauf einstellen!;)

ebenfalls ein angenehmes wochenende!

gruss,
shaba:D
Avatar
14.11.08 18:24:12
Antwort auf Beitrag Nr.: 35.947.790 von shaba am 14.11.08 15:05:14und die windeln werden auch regelmässig "gefüllt"

Windeln hat JNJ nicht. Wenn Du Pampers meinst, dann sind die von PG. Auch das eines der besten Unternehmen weltweit

Aber egal....

Gruss und schönes WoEnde
Avatar
14.11.08 18:42:56
Antwort auf Beitrag Nr.: 35.949.953 von spaceistheplace am 14.11.08 18:24:12Ich sehe schon; ich weiss noch viel zuwenig über JNJ

nochmals, schönes w.ende!

shaba ;)
Avatar
18.11.08 15:13:08
Nicht sehr angenehm!

NEW YORK (Associated Press) - Two Johnson & Johnson subsidiaries that make and distribute a painkilling skin patch must pay nearly $16.6 million to the family of a suburban woman who died from a drug overdose while using the product, a jury ruled Monday.

Janice DiCosolo, 38, of Cicero died on Feb. 15, 2004, while using a Duragesic patch that her doctor prescribed to reduce pain caused by a neurological condition called reflex sympathetic dystrophy, her attorneys said.

The mother of three died because the patch delivered a fatal dose of its main ingredient, the powerful narcotic pain reliever fentanyl, jurors ruled Monday in Cook County Circuit Court following a three-week trial.

The defendants, Titusville, N.J.-based Janssen Pharmaceutica Inc. and Mountain View, Calif.-based ALZA Corp., knew about problems with the Duragesic patch that allowed it to leak fentanyl in doses large enough to kill patients, the lawsuit claimed. Both companies are subsidiaries of New Brunswick, N.J.-based Johnson & Johnson.

"They knew this patch was dangerous and defective but they continued to sell it and make money, and that's the only reason Janice DiCosolo is dead," Jim Orr, an attorney for DiCosolo's family, said in a statement.

Greg Panico, a spokesman for Janssen and ALZA, said Monday that the companies sympathize with DiCosolo's family but disagree with the jury's verdict.

The companies are considering options for an appeal, Panico said in a statement.

"This is a very unfortunate case for everyone, but we maintain that the patch was not defective," he said.

An independent expert and company expert inspected the patch that DiCosolo used and concluded there was no defect, Panico said. The companies believe DiCosolo's cause of death was polypharmacy, "a mix of multiple and potentially incompatible medications," he said.

Duragesic is a prescription-only product that is intended for cancer patients and others with chronic pain and is designed to dispense the medicine slowly through the skin.

The verdict is the fourth trial loss for the companies since 2006, DiCosolo's attorneys said.

A Sanford, Fla., jury last month awarded $13.3 million to the family of Susan Hodgemire, 34, who died after undergoing back surgery and using the Duragesic patch. In June 2007 a federal jury awarded $5.5 million to the father of a 28-year-old man who died in 2003 while wearing the patch.

The Food and Drug Administration issued two warnings in two years about improper use of fentanyl patches.

Some of the deaths came after doctors prescribed the patches to the wrong patients, the FDA said in December 2007. Patients could also accidentally overdose by using the patches wrong, the FDA said.

Some patches containing fentanyl were recalled in February 2008 because of a flaw that could cause them to leak. Those patches were sold in the United States by Actavis South Atlantic LLC and had both that name and the company's former name, Abrika Pharmaceuticals Inc., on the packaging.

Also in February, PriCara, another Johnson & Johnson division announced a recall of fentanyl patches manufactured by ALZA Corp.

The patches were first approved under the brand name Duragesic in 1990. A generic version hit the market in 2005.


http://money.cnn.com/news/newsfeeds/articles/apwire/37006f4b…
Avatar
18.11.08 16:54:53
Das freut uns aber wieder!:laugh:

Magnetically Steered Irrigated Tip Cardiac Catheter for Treatment of Irregular Heart Rhythms Now Available Throughout the European Union
NAVISTAR® RMT THERMOCOOL® combines the safety of power-controlled irrigated tip technology with the control of remote magnetic navigation away from fluoroscopy exposure

Diamond Bar, CA (November 18, 2008) - Patients in the European Union (EU) with Atrial Fibrillation and other arrhythmias, also known as irregular heart rhythms, may now benefit from treatment with an innovative state-of-the art catheter. The NaviStar® RMT ThermoCool® Catheter is designed to maintain safe tip-to-tissue temperatures and gives physicians the safety and convenience of steering the catheter remotely away from fluoroscopy exposure during procedures to eliminate abnormal heart rhythms.

The NaviStar® RMT ThermoCool® Catheter for radiofrequency (RF) ablation is used with the NIOBE® Magnetic Navigation System, which helps steer a catheter remotely and guide ablation to targeted areas that require treatment.

The NaviStar® RMT ThermoCool® Catheter, manufactured by Biosense Webster, Inc., in combination with the Carto® RMT System can be used to create highly accurate 3D electroanatomical maps. Electrophysiologists are able to steer the NaviStar® RMT ThermoCool® Catheter using the integrated NIOBE® Navigation technology and a miniature location sensor is placed inside each catheter for real-time, high-resolution mapping.

“Remote magnetic navigation for Atrial Fibrillation ablation is feasible with a short learning curve,” said Carlo Pappone, MD, PhD, FACC, Director, Department of Arrhythmology, San Raffaele University Hospital, Milan, Italy. “Combined with the proven technology of open irrigation this is an essential tool, especially for complex ablations. As a physician, I am pleased that the product is now widely available.”

The British Standards Institution approved the NaviStar® RMT ThermoCool® Catheter for marketing in August 2008. Earlier this year Biosense Webster had withdrawn the catheter after an external evaluation of the product at nine sites within the EU and Canada. At that time, the company determined that the catheter was performing in a manner inconsistent with the product’s specifications. The inconsistencies have now been rectified, the external evaluation has been completed and the product is available throughout the EU.

RF ablation procedures are most often used to treat rapid, irregular heartbeats (cardiac arrhythmias). The procedure is performed by a doctor guiding the NaviStar® RMT ThermoCool® Catheter with the Niobe® Magnetic Navigation System to the area of heart muscle where cells are giving off electrical signals that stimulate the abnormal heart rhythm. An application of energy is then transmitted to those areas to carefully destroy those heart muscle cells that are conducting the extra impulses that caused the irregular heart rhythm.

“As leaders in electrophysiology, we take pride in transforming insightful ideas from the electrophysiology lab into enhanced technologies that improve procedures and make a difference for patients,” said Shlomi Nachman, Worldwide President, Biosense Webster, Inc. “We are pleased to officially launch this exciting product to electrophysiologists in the EU.”

Dr. Pappone is compensated for his services as a consultant to the Company.

About Biosense Webster, Inc.

Biosense Webster, Inc., a Johnson & Johnson company, pioneered EP diagnostic catheters more than 30 years ago and continues to lead the industry as an innovative provider of advanced diagnostic, therapeutic and mapping tools. As the leader in navigation systems, Biosense Webster, Inc.'s, technology includes the largest installed base of navigation systems worldwide in leading hospitals and teaching institutions. With proprietary products such as the CartoMerge™ Image Integration Software Module, the ThermoCool® Irrigated Tip Catheter and the Lasso® Circular Variable Mapping Catheter, the company is changing the way electrophysiologists diagnose and treat arrhythmias.

http://www.jnj.com/connect/news/all/20081118_080000
Avatar
18.11.08 17:06:39
Antwort auf Beitrag Nr.: 35.992.606 von shaba am 18.11.08 16:54:53dem Kurs schadet oder bringts heute jedenfalls nicht viel. ich weiß auch nicht, wie stark solche meldungen auf die gewinnsituation dieses Großkonzernes wirken. Dürfte marginal sein...:D

Gruss space
Avatar
18.11.08 17:44:08
Antwort auf Beitrag Nr.: 35.992.774 von spaceistheplace am 18.11.08 17:06:39naja, ganz so schlecht ist der kurs ja doch nicht, im Moment wieder über 60$ und wenn der DOW weiter steigt oder zumindest diese +1,5% halten kann wirds wohl noch weitergehen.

Gruß,
shaba ;)
Avatar
18.11.08 18:55:21
Antwort auf Beitrag Nr.: 35.993.304 von shaba am 18.11.08 17:44:08naja, ganz so schlecht ist der kurs ja doch nicht, im Moment wieder über 60$ und wenn der DOW weiter steigt oder zumindest diese +1,5% halten kann wirds wohl noch weitergehen.

bei dieser Volatilität aktuell, auch im DOW ist es heiteres beruferaten zu prognostizieren, wo der Dow schließen wird. ist gerade jeden tag so.
daher schaue ich gar nicht mehr groß hin, sollen sich alle austoben, ist mir egal.
Denn diese Kursschwankungen ändern am Unternehmen nichts.

Gut möglich, dass der DOW auch auf 7000 oder 6000 fallen kann, jedoch sollte das einen nicht beunruhigen.

nach dieser Krise werden wir jedenfalls gesündere Strukturen in der Finanzwelt haben...

Gruss space
Avatar
20.11.08 08:52:00
Antwort auf Beitrag Nr.: 35.994.293 von spaceistheplace am 18.11.08 18:55:21Guten Morgen,

ja die Vola ist sehr groß und der Dow fiel gestern unter die berüchtigte 8000er Marke. Nach Ansicht der Charttechniker darf er sich dort nicht sehr lange aufhalten, sonst besteht die Gefahr dass er durchrasselt u.U. bis auf erschreckende 4000!! :eek:

Der Wert eines Unternehmens ist sehr wichtig, spielt jedoch mMn in panischen Momenten keine Rolle, der Kurs wird einfach mitgerissen.

Wollen wir hoffen dass der Dow wieder über die bewusste Marke geht und dieser "Worst Case" nicht eintritt!

Gruß,
Shaba
Avatar
20.11.08 20:25:22
Nicht besonders angenehm!

LONDON, Nov 20 (Reuters) - Approval for Johnson & Johnson (JNJ.N: Quote, Profile, Research, Stock Buzz) to sell its pain medicine Ionsys in Europe should be suspended because of a defect with the drug's delivery system that could lead to overdose, the European Medicines Agency (EMEA) said on Thursday.

The stock fell 1.8 percent to $57.03, helping to pull the Dow Jones Pharmaceuticals Index .DJUSPR down 0.26 percent after the European Medicines Agency's announcement.

Recommendations by the agency's Committee for Medicinal Products for Human Use (CHMP) are normally endorsed by the European Commission.

The agency said a defect with the delivery system of the medicine indicated to ease post-operative pain could lead to patients being overdosed. The drug is marketed in Europe by J&J unit Janssen-Cilag.

Janssen-Cilag told the agency that it had detected corrosion of a component in the delivery system in batch of the drug, which could trigger self activation of the system, causing an overdose.

An overdose could cause respiratory depression, a life-threatening complication.

The company said it has not been able to identify the cause of the defect, or pick it up with its testing system.

However there have been no reports of serious adverse events associated with the malfunction of the device -- in particular related to self-activation of the system -- or of an overdose as a result, the agency added.

(Reporting by Ben Deighton; editing by Michael Kahn and Elaine Hardcastle)



Gruß,
shaba :confused:
Avatar
21.11.08 13:19:27
besonders angenehm:

FDA panel backs new use for J&J catheter system
Thursday November 20, 8:41 pm ET
FDA panel says J&J catheter should be approved for new use against heart spasms

WASHINGTON (AP) -- Johnson & Johnson said late Thursday a panel of government advisers recommended that its catheter system be approved for a new use in treating irregular heart rhythms.

A Food and Drug Administration panel of medical device experts unanimously voted in favor of approving the Thermocool family of catheters for the new use, with certain conditions. Panelists said the company should be required to educate physicians on proper use of the device and operate a registry of patient outcomes.

ADVERTISEMENT
The FDA is not required to follow the panel's advice, though it usually does.

New Brunswick, N.J.-based J&J is seeking an approval to treat atrial fibrillation, which causes the upper chambers of the heart to contract irregularly.

About 2.2 million adults in the U.S. have the condition, which accounts for about 15 percent of strokes, according to the American Heart Association. Doctors currently treat those patients by prescribing blood thinning drugs.

Studies conducted by J&J showed 62.7 percent of patients treated with the catheter were free from fibrillation symptoms nine months after treatment, compared with 17.2 percent of those taking traditional drug therapy.

If cleared by regulators, J&J's device would be the first catheter on the market specifically indicated to treat atrial fibrillation. Competitors like St. Paul-based Jude Medical are also working to win the designation.

Shares of Johnson & Johnson rose 1 cent to $55.82 in after-hours trading, after falling $2.31, or 4 percent, to close at $55.81 in regular trading.
Avatar
21.11.08 14:15:15
Antwort auf Beitrag Nr.: 36.032.197 von spaceistheplace am 21.11.08 13:19:27ja, das kann man sicher zu den angenehmen bekanntmachungen zählen.

leider kann sich auch JNJ nicht vom umfeld abnabeln und der kurs geht gegen süden, wie bei vielen anderen gut aufgestellten unternehmen.
ich gehe davon aus dass es einen crash geben wird und der dow bis auf 6000 oder auch noch tiefer fallen wird.

mal sehen was sich heute abspielen wird, der dow-fut ist zwar im plus dzt. und es könnte einen rebound geben, oder der kurs sackt weiter ab.
Avatar
21.11.08 19:04:14
Antwort auf Beitrag Nr.: 36.032.939 von shaba am 21.11.08 14:15:15mal sehen was sich heute abspielen wird, der dow-fut ist zwar im plus dzt. und es könnte einen rebound geben, oder der kurs sackt weiter ab.

das weiß man aktuell an der wallstreet noch nicht mal ne Stunde vor handelsschluss bei den Kapriolen. ich tippe mal auf ein Minus vor dem Wochenende. da lehnt sich keiner aus dem Fenster...

Gruss und Nerven behalten
space
Avatar
21.11.08 19:34:20
Antwort auf Beitrag Nr.: 36.037.019 von spaceistheplace am 21.11.08 19:04:14Nerven behalten bin ich gewöhnt bin ja auch seit Jahren bei einem Biotechunternehmen investiert (INTERCELL), die stehen kurz vor der ersten Zulassung.
Ich meine dass uns der Markt noch seine schlechten Seiten zeigen wird und gehe davon aus dass es noch viel weiter runtergehen kann.
Fachleute aus meinem Freundeskreis sehen den Dow bei 6000 oder sogar darunter.:confused:

Gruß und ein angenehmes Wochenende:
Avatar
24.11.08 14:02:07
Johnson & Johnson übernimmt Omrix Biopharmaceuticals


New Brunswick, NJ (aktiencheck.de AG) - Der amerikanische Gesundheitskonzern Johnson & Johnson (ISIN US4781601046/ WKN 853260) gab am Montag bekannt, dass er die Omrix Biopharmaceuticals Inc. (ISIN US6819891093/ WKN A0JKKN), ein voll integriertes biopharmazeutisches Unternehmen, für rund 438 Mio. Dollar in bar übernehmen wird.
Im Rahmen der Transaktion erhalten Omrix-Aktionäre für jeden ihrer Anteilsscheine 25,00 Dollar in bar. Die Übernahme soll bis Ende Dezember 2008 abgeschlossen sein. Sie wird das EPS-Ergebnis des Konzerns in 2009 nicht oder leicht negativ beeinflussen.

Nach Abschluss der Übernahme erwartet der Konzern eine einmalige Sonderbelastung in Höhe von rund 120 Mio. Dollar nach Steuern im Zusammenhang mit IPR&D (In-Process Research and Development)-Abschreibungen.

Die Aktie von Johnson & Johnson schloss am Freitag an der NYSE bei 58,35 Dollar, die von Omrix Biopharmaceuticals an der NASDAQ bei 21,16 Dollar. (24.11.2008/ac/n/a)

Quelle: Finanzen.net 24.11.2008 13:17:00
Avatar
27.11.08 14:21:38
nun ja, da hat JNJ zu Recht was auf die Mütze bekommen...solch ne Kampagne ist voll daneben...

Twitter-Bloggerin zwingt Johnson & Johnson zum Kampagnenstopp

dp

27.11.2008 11:40

Johnson & Johnson verärgert junge Mütter, die ihrem Ärger im Web Luft machen

Die Macht von Twitter bekam der US-Konzern Johnson & Johnson zu spüren. Mit einer Kampagne für das Schmerzmittel "Motrin" löste das Unternehmen den Zorn einer Twitter-Bloggerin aus. Und die brachte eine Lawine ins Rollen.

Unternehmen, die die Macht von Weblogs oder Microblogging-Diensten wie Twitter noch immer ignorieren, werden durch ein aktuelles Beispiel von Johnson & Johnson vielleicht eines Besseren belehrt: Wie das US-Marketingfachblatt "Adage" berichtet, hat der Markenartikler sich den Zorn junger Mütter zugezogen, indem es in einer Kampagne Verspannungsschmerzen ansprach, die durch den aktuellen Trend, Babys und Kleinkinder eng am Körper zu tragen, ausgelöst werden. Doch der Einstiegssatz der Kampagne "Wearing your baby is in fashion", die für das Schmerzmittel "Motrin" werben sollte, verärgerte die US-Bloggerin Jessica Gottlieb, die ihren Unmut auf Twitter bei ihren 1.018 Followern kund tat.

Eine andere Bloggerin und Webshop-Betreiberin für Kindermode mit 4.221 Twitter-Anhängern griff das Thema auf und bastelte ein neunminütiges Youtube-Video mit dem Titel "Motrin Ad Makes Moms Mad", in dem verärgerte Mütter die Kampagne kommentierten. 70.000 Youtube-Nutzer riefen das Video ab und stellten ihrerseits Boykott-Videos gegen Johnson & Johnson und das Medikament "Motrin" ins Netz.

Das Ergebnis: Johnson & Johnson stellte die Kampagne ein und entschuldigte sich im Web offiziell bei allen Müttern: "We have heard your concerns about the ad that was featured on our website. We are parents ourselves and we take feedback from moms very seriously. We are in process of removing this ad from all media. It will, unfortunately, take a bit of time to remove it from our magazine advertising, as it is on newsstands and in distribution. Thank you for your feedback. It's very important to us", so die offizielle Erklärung.
Avatar
27.11.08 14:32:28
Antwort auf Beitrag Nr.: 36.091.049 von spaceistheplace am 27.11.08 14:21:38da hat JNJ zu Recht was auf die Mütze bekommen.

naja, wir anleger aber auch!
bei diesem giga unternehmen wird das keine große rolle spielen, die spenden ein paar millionen an irgendeinen frauen/mütter fond und alles ist wie vorher.
mehr sorgen aber macht mir die allgemeine situation in den staaten und in der welt, da wird ungedecktes geld gedruckt, da werden bilanzen mit falschen daten manipuliert, wen das mal gut geht?!

ich meine daß es in den nächsten monaten noch einen gewaltigen rutsch nach unten geben wird und der dow bei 6000 oder gar darunter zu sehen sein wird.

gruß
Avatar
27.11.08 15:07:32
Beitrag Nr. 100 ()
Antwort auf Beitrag Nr.: 36.091.183 von shaba am 27.11.08 14:32:28da wird ungedecktes geld gedruckt
Für Sachwertbesitzer ist das relativ gleich. Das alle Maßnahmen der Staaten auf eine mehr oder weniger starke Inflation hinauslaufen, sollte uns nicht so sehr interessieren. Die Papiergeldbesitzer und Anleihenanleger sollten sich darum mehr Sorgen machen.

da werden bilanzen mit falschen daten manipuliert
Wer manipuliert wo? Beweise?
Avatar
27.11.08 15:15:20
Beitrag Nr. 101 ()
Antwort auf Beitrag Nr.: 36.091.630 von Larry.Livingston am 27.11.08 15:07:32gemeint sind; die neuen von der eu genehmigten bilanzregeln, wo uneinbringliche verluste "einbalsamiert" werden und als aktiva in den bilanzen aufscheinen dürfen.
Avatar
27.11.08 15:49:59
Beitrag Nr. 102 ()
Antwort auf Beitrag Nr.: 36.091.726 von shaba am 27.11.08 15:15:20Du sprichst sicher darauf an das die Zügel bei den Bilanzierungsregeln deutlich gelocker wurden. Das trifft in erster Linie Finanzunternehmen, Banken und Versicherungen.
Hintergrund ist folgender: im Zuge der Krisen und Tumulte mussten Abschreibungen auch auf werthaltige Assets vorgenommen werden, einfach weil der Markt sehr illiquide und ineffizient wurde und eigentlich nur noch AAA Staatsanleihen in einigermaßen anständigen Volumen gehandelt werden können/konnten. Das hatte zur Folge das wie bei einer Kettenreaktion immer mehr und mehr abgeschrieben werden musste - auch bei werthaltigen Assets, vor allem deswegen weil es an der Liquidität für einen ordnungsgemäßen Handel und marktgerechten Preisen fehlt(e) - und dies dann in einen regelrechten, sich selbst beschleunigenden Abwärtsstrudel endete. Als man merkte das es nicht einfach nur ausreichte den Banken Liquidität zur Verfügung zu stellen, welche sie hamsterten statt zu handeln - denn sei misstrau(t)en den anderen Banken aufgrund derer Abschreibungen - hofft man darauf das dies ein Ende der Abschreibungen provizieren könnte. Leider heißt das auch das Schrottassets gehoben werden dürfen die wirklich nicht werthaltig sind und bei denen die Abschreibungen berechtigt sind.

Staples und Healt-Care Unternehmen dürfte das wenig jucken. In JNJs Bilanz gibt es keinen Schrott zu heben.
Avatar
27.11.08 16:10:20
Beitrag Nr. 103 ()
Antwort auf Beitrag Nr.: 36.092.193 von Larry.Livingston am 27.11.08 15:49:59bin etwas überrrascht über eine so umfangreiche und erklärende antwort!
ja tatsächlich ist es so mit den banken, vor allem den banken welche in den cee staaten stark engagiert sind.
ich bin österreicher und man hat in der letzten woche bei uns festgestellt das unsere banken mit 85% des bip´s
in diesen länder investiert sind, einfach wahnsinn wenn man bedenkt daß es dzt errechnet. zwischen 30 u. 50% ausfälle bei den gewährten krediten geben wird!!

die brd lediglich mit einem bruchteil davon, ich glaube mich zu erinnern so zwischen 10 und 20% des bip´s.

ja, jnj ist ein sicherer hafen in welchen ich erst vor kurzem gelandet bin, sonst habe ich im portfolio eine biotech aktie, welche in diesen tagen ihr erstes produkt genehmigt bekommt.

gruß
shaba ;)
Avatar
27.11.08 16:19:05
Beitrag Nr. 104 ()
Antwort auf Beitrag Nr.: 36.092.520 von shaba am 27.11.08 16:10:20ja, jnj ist ein sicherer hafen in welchen ich erst vor kurzem gelandet bin, sonst habe ich im portfolio eine biotech aktie, welche in diesen tagen ihr erstes produkt genehmigt bekommt.

nur 2 Werte im Depot?
Okay, JNJ ist ja fast wie ein Fonds aus Pharma, Medtech und Staples, aber dann noch ein wohl riskantes Biotechunternehmen?
Willst Du investieren oder spielen?

Gruss space
Avatar
27.11.08 16:38:32
Beitrag Nr. 105 ()
Antwort auf Beitrag Nr.: 36.092.649 von spaceistheplace am 27.11.08 16:19:05ich bin der meinung mit meinem invest nicht zu spielen, das ist mmn die beste aktie im atx, voll im cash und dzt sehr günstig zu kaufen, schau die mal die webisite und die letzten bewertungen an;

]http://www.intercell.com

ich habe vor einigen jahren diese aktie gekauft, bereits mehrmals "kassa gemacht" und jetzt bzw. im kommenden jahr wird sie gegen 40 euro gehen. das unternehmen ist voll im cash und die perspektiven sind gewaltig.

deine meinung würde mich interessieren, muß ja nicht gleich sein!

gruß
Avatar
27.11.08 17:07:36
Beitrag Nr. 106 ()
Antwort auf Beitrag Nr.: 36.092.921 von shaba am 27.11.08 16:38:32deine meinung würde mich interessieren, muß ja nicht gleich sein!

Sorry, ich bin kein Doc oder Mediziner, um ein Biotech-Unternehmen beurteilen zu können bzw. ob deren Produkt(e) auf den markt kommen werden oder wenn sie da sind sich behaupten.
Die Biotechbranche ist die für mich am schwierigsten zu beurteilende Branche als Laie überhaupt. man ist auf Fachkommentare angewiesen und um deren Qualität seitens der Analoschar ist meist äüßerste Vorsicht geboten.

Ich kaufe daher Biotechs generell nicht und kümmere mich nicht darum.
Gibts hier kleinen Thread dazu? Sonst würde ich an Deiner >Stelle mal einen aufmachen.

Gruss space
Avatar
27.11.08 17:20:10
Beitrag Nr. 107 ()
Antwort auf Beitrag Nr.: 36.093.316 von spaceistheplace am 27.11.08 17:07:36es gibt natürlich auch im wo einen thread dazu.

ich bin bestens informiert über diese aktie.
dieses unternehmen ist komplett ausfinanziert, in den nächsten tagen wird es eine zulassung geben, eine impfung gegen die japanischen enzyphalits und einen vertrag mit der us army für die marin´s in südostasien. ebenso die zulassung für canada, europa und australien.

ich bin auch kein doktor oder habe keine ausbildung in dieser richtung, aber ich kenne jede einzelne phase dieses unternehemns und ebenso die umfangreichen produkte in der pipeline. meine risiko besteht darin daß ein ein pharmagigant die ganze "klitsche" um 40-50 euro kauft und aus ist der traum.
wenn die selbsständig bleiben können, adnn errreichen sie in 5-7 jahren 100euro per stück, oder gar noch mehr.

so das wars, aufgrund der anstehenden meldungen liegt die aktie heute wieder 10% im plus.

gruß ;)
Avatar
28.11.08 13:02:11
Beitrag Nr. 108 ()
naja:

Johnson & Johnson receives FDA complete response letter for ceftobiprole
27th November 2008
By Staff Writer
Johnson & Johnson Pharmaceutical R&D has received a complete response letter from the FDA regarding its new drug application for ceftobiprole for the treatment of complicated skin and skin structure infections, including diabetic foot infections.

Print Article
Email A Friend
Your Comment
Post to del.icio.us
Digg this
Click here to find out more!

RELATED ARTICLES

* Johnson & Johnson: pharmaceutical sales growth�for now
25 Jan 2008
* Tibotec/Johnson & Johnson: Intelence provides new option in late-stage HIV
21 Jan 2008
* Johnson and Johnson: FDA extends review of ustekinumab by three months
12 Aug 2008
* Centocor/Johnson & Johnson: SONIC trial results support Remicade
8 Oct 2008
* PTG in-licenses bioresorbable polymers from Bezwada Biomedical
29 May 2008

COMPANIES MENTIONED
No companies found
WHITE PAPERS
No White Papers Available
Click here to find out more!

The FDA has indicated that they cannot approve the NDA for ceftobiprole at this time. They have asked Johnson & Johnson Pharmaceutical R&D (J&JPRD) to conduct additional audit work of clinical investigator sites and to address specific questions related to site monitoring.

J&JPRD and its co-development partner, Switzerland-based Basilea Pharmaceutica are reviewing the complete response letter and will continue to work with the FDA to resolve questions that are outlined in the complete response letter.

Ceftobiprole is a novel, broad-spectrum, anti-MRSA cephalosporin with activity against methicillin-resistant Staphylococcus aureus (MRSA), penicillin-resistant Streptococcus pneumonia and many clinically important gram-negative bacteria, including Pseudomonas.
Avatar
29.11.08 10:37:51
Beitrag Nr. 109 ()
Antwort auf Beitrag Nr.: 36.102.370 von spaceistheplace am 28.11.08 13:02:11naja, spaceistheplace

das sind aber schon zwei paar schuhe, die haut ist nicht so extrem gefährdet in spital und auch leichter zu behandel.

bei sal.aureus geht es um frisch operierte herz-nieren usw.- patienten, welche sich mit den in allen spitälern vorhandenen bakterien infiszieren und daran sterben.

heute ist die gefahr bei einer herzoperation nicht mehr die operation selbst, sondern die ansteckungsgefahr im spital(spitalskrankheit!), die operation selbst ist schon längst routine!

intercell bzw. merck (usa)sind da bereits weit forgeschritten, merck trägt die kosten, intercell liefert das patentierte grund vaccine und ist am späteren ertrag mit 10% vom umsatz dabei. der markt wird jährlich auf 3milliarden us$ geschätzt!
Avatar
30.11.08 06:09:18
Beitrag Nr. 110 ()
Antwort auf Beitrag Nr.: 36.113.903 von shaba am 29.11.08 10:37:51ist nicht unbedingt alles aus gold was da so glänzt, aber J&J wird das sicher durchstehen und weiterglänzen!;)

It's not good enough for a company just to have clinical trial data showing that its drug works; the Food and Drug Administration has to actually believe that the data is real.

Unfortunately for Johnson & Johnson (NYSE: JNJ) and Swiss drugmaker Basilea Pharmaceutica, the agency appears a little reluctant to take some of the data for the drugmakers' antibiotic ceftobiprole at face value. The FDA has asked the companies to "conduct additional audit work of clinical investigator sites and to address specific questions related to site monitoring" before resubmitting their marketing application.

Site monitoring is a big deal. Independent doctors are usually on the front lines of clinical trials, and it’s the company's responsibility to make sure the doctors are following the procedural setup before the trial begins. Redoing a trial because of a screw-up could be a very costly process.

Fortunately for Johnson & Johnson, there's some precedence for this. Theravance (Nasdaq: THRX) ran into the same issue about problems with monitoring a clinical site for a trial testing its antibiotic telavancin, but an FDA advisory committee eventually gave it a thumbs-up, so Johnson & Johnson's delay might not be the end of the world.

Lately, the FDA seems to be especially harsh on antibiotic drugs, and on Johnson & Johnson in particular. The agency turned down marketing applications for Johnson & Johnson's Doribax -- and an earlier ceftobiprole application -- as well as Wyeth's (NYSE: WYE) Tygacil earlier this year. An advisory panel wasn't so hot on Targanta Therapeutics' oritavancin last week, either, causing shares in that company to tank.

Whether this is a permanent change in standards that might reduce future competition for current antibiotic makers like Cubist Pharmaceuticals (Nasdaq: CBST) and ViroPharma (Nasdaq: VPHM) or just an unrelated rash of rejections is a bit of a mystery. Investors should be able to get a better handle on the situation when the agency makes a final decision on telavancin. They should also keep an eye on how easily Johnson & Johnson can bounce back from the latest rejections.

http://www.fool.com/investing/dividends-income/2008/11/28/th…
Avatar
01.12.08 14:46:16
Beitrag Nr. 111 ()
JNJ kauft Brustimplantatefirma....ist ne "Wachstumsbranche"...:laugh::laugh::laugh:

Gruss space

01.12.2008 14:38
UPDATE 1-J&J to buy breast implant firm Mentor for $1.1 bln

NEW YORK, Dec 1 (Reuters) - Johnson&Johnson (News/Aktienkurs) said on Monday it would acquire breast implant maker Mentor Corp for $1.07 billion as the giant diversified healthcare company pushes into the market for aesthetic medical products.

At $31 per share, J&J's tender offer for Mentor is a 92 percent premium to Mentor's closing price on Friday, although the shares had traded above $40 at the start of 2008.

J&J, which plans to run Mentor as a standalone business under its Ethicon division, said the acquisition would strengthen its presence in aesthetic and reconstructive medicine.

The deal, which was approved by both companies' boards, is expected to close in the first quarter of 2009. It is expected to hurt earnings per share by about 3 cents to 5 cents, J&J said.

J&J said the deal has a net value of $1.12 billion including debt.

(Reporting by Lewis Krauskopf, editing by Gerald E. McCormick)

((lewis.krauskopf@thomsonreuters.com; 646-223-6082;Reuters Messaging:Lewis.Krauskopf.reuters.com@reuters.net)) Keywords: JOHNSON&JOHNSON MENTOR/

(Multimedia versions of Reuters Top News are now available for: * 3000 Xtra: visit http://topnews.session.rservices.com * BridgeStation: view story .134 For more information on Top News: http://topnews.reuters.com)

COPYRIGHT
Avatar
01.12.08 15:06:52
Beitrag Nr. 112 ()
Antwort auf Beitrag Nr.: 36.123.574 von spaceistheplace am 01.12.08 14:46:16wahrlich-wahrlich :laugh:;):laugh:;)

gruß shaba :D
Avatar
05.02.09 20:29:47
Beitrag Nr. 113 ()
Da es noch keiner reinkopiert hat, gibts hier die letzten Quartalszahlen:

Johnson & Johnson 4Q profit rises 14 percent

By LINDA A. JOHNSON – Jan 20, 2009

TRENTON, N.J. (AP) — Health care products maker Johnson & Johnson on Tuesday posted a 14 percent increase in fourth-quarter profit, topping Wall Street forecasts, as big one-time gains offset slumping sales.

But the maker of baby shampoo, contraceptives and other health items forecast weaker results in 2009, blaming the global recession, unfavorable currency exchange rates and intensified pressure from both generic drugs and competitors' new products.

Still, its CEO said the economic uncertainty and J&J's strong cash flow — $12.2 billion in 2008 — put the company "in a great position" to acquire companies or products.

New Brunswick, N.J.-based J&J earned $2.71 billion, or 97 cents per share, up from $2.37 billion, or 82 cents per share, in the year-ago quarter. Revenue fell 4.9 percent to $15.18 billion from $15.96 billion — the first drop since the end of 2004.

Excluding charges and gains, J&J earned 94 cents a share. Analysts polled by Thomson Reuters expected profit of 92 cents per share on revenue of $15.93 billion. The one-time items included a $141 million research charge, and $638 million in income for favorable settlements of lawsuits and other items.

Analysts called it a "decent" quarter but were disappointed by the reduced 2009 forecast.

"Initially, it threw people for a loop," said health care analyst Tim Nelson of First American Funds.

William Weldon, chief executive and chairman, said J&J's fourth-quarter revenues were reduced across the board by the global recession, as people worried about unemployment and losing health insurance cut back on doctor visits, elective surgery and use of prescription medicines. He noted that sales of consumer items such as contact lenses and diabetes test strips have fallen as "consumers are becoming more frugal."

"I don't think we're going to see a reversal in the near term," Weldon told The Associated Press in an interview.

Unfavorable currency rates cut J&J's fourth-quarter revenue by 3.9 percent — after favorable rates boosted sales so much earlier in 2008 that they still lifted revenue by 2.4 percent for the full year.

The company issued a 2009 forecast for earnings of $4.45 to $4.55 per share. That's below average analyst estimates of $4.61, which J&J said excludes the 3-cent to 5-cent impact of buying breast implant and cosmetic product maker Mentor Corp., a deal set to close this month. Johnson & Johnson included that amount in its forecasts.

"They are rightly conservative in their 2009 guidance," given the volatility in currency markets and cutbacks in consumer health spending, said health care analyst Les Funtleyder of Miller Tabak & Co.

Despite that, Weldon sounded optimistic, especially about chances for snapping up companies, products or medicines in development.

"I think the opportunities this year are going to be extraordinary," Weldon told analysts.

He said in an interview that J&J is reviewing possible deals across all its businesses.

"We have the financial strength to do probably anything we want," Weldon said.

Funtleyder said J&J will have chances to do deals, because many health care companies need capital, but perhaps not till 2010.

The quarterly revenue drop was led by an 11 percent plunge in pharmaceutical sales to $5.7 billion. That decline was partly due to a 66.5 percent drop in sales of schizophrenia drug Risperdal, which got generic competition last June. Pain patch Duragesic and Razadyne, for dementia related to Alzheimer's disease, also have generic competitors.

"We expected it to be bad, but it was worse than expected," Nelson said of the segment.

Medical-device sales fell by 2 percent, to $5.6 billion. Consumer products eked out a 1.2 percent increase in sales to $3.9 billion, helped by the launch of allergy treatment Zyrtec as an over-the-counter medicine and the purchase of Chinese skin-care company Dabao.

Globally, sales were down in every region but Asia/Pacific and Africa.

Weldon noted that J&J has bought back $8.1 billion worth of its shares under a $10 billion buyback program.

"We were the third-best performer in the Dow for 2008," with share price down only 8 percent, compared with 30 percent or more for some stock indexes, he said.

For the full year, net income jumped 22 percent, to $12.95 billion, or $4.57 per share, while revenue rose 4.3 percent, to $63.75 billion.

Johnson & Johnson shares closed down 69 cents, or 1.2 percent, at $56.75.
Avatar
23.03.09 10:40:39
Beitrag Nr. 114 ()
Antwort auf Beitrag Nr.: 36.522.569 von RayNar am 05.02.09 20:29:47Johnson & Johnson Investors Will Feel Pain Before Gain - UBS

http://seekingalpha.com/article/127226-johnson-johnson-inves…
Avatar
23.04.09 20:46:02
Beitrag Nr. 115 ()
Antwort auf Beitrag Nr.: 36.823.470 von RayNar am 23.03.09 10:40:39Wie jedes Jahr (ununterbrochen seit 47 Jahren):
JnJ hebt die Dividende an.. :cool:

http://finance.yahoo.com/news/Johnson-amp-Johnson-Announces-…
Avatar
01.07.09 10:40:41
Beitrag Nr. 116 ()
Sehr hübsch anzusehen ;)
Avatar
01.07.09 14:29:21
Beitrag Nr. 117 ()
Danke für die schöne Grafik!
Als buy n' hold Aktionär könnte ich mir tagelang solch wunderbaren Grafiken ansehen ohne dabei müde zu werden ;)
Avatar
01.07.09 15:02:51
Beitrag Nr. 118 ()
Antwort auf Beitrag Nr.: 37.500.384 von mike_N am 01.07.09 14:29:21bei einer 5 jährigen Graphik bist du aber alles andere als ein buy&hold Aktionär. Buy and hold heißt für mich ab 20Jahre bis immer, so wie ích es halte
Avatar
01.07.09 19:47:49
Beitrag Nr. 119 ()
Natürlich ist mein Zeithorizont "auf immer und ewig" (buy+hold heisst ja im prinzip genau das). Bei JnJ bin ich erst in den letzten 2 Jahren eingestiegen.

Du hast recht, ein 5 Jahres-Chart ist in der Regel nur ein schönes Bildchen. In diesem Fall zeigt es jedoch sehr schön, wie günstig JNJ geworden ist.

Bei meinen Kaufentscheidungen studiere ich die Geschäftsberichte der letzten 10 Jahre. Dazu muss das Geschäft schon seit Jahrzehnten einen stetigen/stabilen verlauf genommen haben.
Mein Depot: PMI, JNJ, KO, Brk, MO, Nestle
Avatar
02.07.09 17:34:37
Beitrag Nr. 120 ()
Antwort auf Beitrag Nr.: 37.502.828 von mike_N am 01.07.09 19:47:49was für ein Zufall, meine langfristigsten Positionen sind ebenfalls Brk, Nestle, KO, PG, JNJ, MO, GE sowie Aflac und Stryker, diese Werte werden nicht verkauft (außer es gibt massivstes Zuwiederhandeln gegen Aktionärsinteressen oder einen Nachhaltiges Problem des Unternnehmens). Dazu mische ich noch ein paar Value Smallcaps wie Rosenbauer, Palfinger etc
Avatar
02.07.09 18:15:45
Beitrag Nr. 121 ()
Hey Jungs!
Ihr habt coole Werte, genau solche diskutieren wir hier. Schaut doch mal rein und diskutiert mit:
Thread: Gewinnerbranchen der Jahre 2006 bis 2040
Avatar
02.07.09 18:24:33
Beitrag Nr. 122 ()
Antwort auf Beitrag Nr.: 37.509.243 von Simonswald am 02.07.09 18:15:45müsstest mich auch hier schon kennen, poste hier auch zeitweise mit, lese hier jeden tag mit, superinteressant
Avatar
30.08.09 09:49:38
Beitrag Nr. 123 ()
ist zwar schon älter aber hier noch nicht kommuniziert worden:

Johnson & Johnson meldet Umsatz- und Ergebnisrückgang, schlägt Erwartungen


New Brunswick, NJ (aktiencheck.de AG) - Der amerikanische Mischkonzern Johnson & Johnson (ISIN US4781601046/ WKN 853260) musste im zweiten Quartal 2009 insbesondere infolge von Währungseffekten einen rückläufigen Umsatz und Gewinn ausweisen. Die Erwartungen wurden indes geschlagen.
Wie der hauptsächlich auf Konsumgüter und Medizintechnik spezialisierte Konzern am Dienstag erklärte, sank der Umsatz auf 15,24 Mrd. Dollar, nach 16,45 Mrd. Dollar im Vorjahresquartal. Das entspricht einem Minus von 7,4 Prozent.

Ferner schrumpfte der Nettogewinn um 3,6 Prozent von 3,33 Mrd. Dollar bzw. 1,17 Dollar je Aktie auf nun 3,21 Mrd. Dollar bzw. 1,15 Dollar. Analysten hatten zuvor nur ein EPS von 1,11 Dollar sowie einen Umsatz von 15,02 Mrd. Dollar erwartet.

Für das Gesamtjahr liegen die Analystenschätzungen bei einem EPS von 4,51 Dollar sowie einem Umsatz von 60,38 Mrd. Dollar. Der Konzern selbst bestätigte seine EPS-Prognose für 2009 von 4,45 bis 4,55 Dollar.

Die Aktie von Johnson & Johnson schloss gestern an der NYSE bei 57,72 Dollar. (14.07.2009/ac/n/a)

Quelle: Finanzen.net 14.07.2009 14:29:00
Avatar
17.09.09 11:55:13
Beitrag Nr. 124 (